{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2\nCandidate Name: RAMATROBAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2\nCandidate Name: RAMATROBAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCOC(=O)Cn1cc(I)c(=O)c(I)c1\nName: PROPYLIODONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 447.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCOC(=O)Cn1cc(I)c(=O)c(I)c1\nName: PROPYLIODONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 447.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\n[Ca]\nName: CALCIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 40.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\n[Ca]\nName: CALCIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 40.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(S(=O)(=O)NC(=O)NC2CCCCCCC2)cc1\nCandidate Name: GLYOCTAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(S(=O)(=O)NC(=O)NC2CCCCCCC2)cc1\nCandidate Name: GLYOCTAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nC[C@]12N[C@H](Cc3ccccc31)c1ccccc12\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DIZOCILPINE\n\n### Structure\n```\nC[C@]12N[C@H](Cc3ccccc31)c1ccccc12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 221.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.15 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 12.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.720\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nC[C@]12N[C@H](Cc3ccccc31)c1ccccc12", "output": "## Molecular Property Analysis: DIZOCILPINE\n\n### Structure\n```\nC[C@]12N[C@H](Cc3ccccc31)c1ccccc12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 221.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.15 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 12.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.720\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1\nALVOCIDIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1\nALVOCIDIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC1(CN2CCN(C)CC2)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O\nDrug Name: PIPEBUZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC1(CN2CCN(C)CC2)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O\nDrug Name: PIPEBUZONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCNC(=O)NC1CCN(c2ncnc3cc(OC)c(OC)cc23)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: BUQUINERAN\n\n### Structure\n```\nCCCCNC(=O)NC1CCN(c2ncnc3cc(OC)c(OC)cc23)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 387.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.72 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 88.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.710\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCNC(=O)NC1CCN(c2ncnc3cc(OC)c(OC)cc23)CC1", "output": "## Molecular Property Analysis: BUQUINERAN\n\n### Structure\n```\nCCCCNC(=O)NC1CCN(c2ncnc3cc(OC)c(OC)cc23)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 387.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.72 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 88.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.710\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccccc1C(OCCN(C)C)c1ccccc1.Cl\nORPHENADRINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccccc1C(OCCN(C)C)c1ccccc1.Cl\nORPHENADRINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCNCC(O)COc1ccc2c(=O)cc(-c3ccccc3)oc2c1\nName: FLAVODILOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCNCC(O)COc1ccc2c(=O)cc(-c3ccccc3)oc2c1\nName: FLAVODILOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nO=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ANAGRELIDE\n\n### Structure\n```\nO=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 256.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.93 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 44.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.770\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nO=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1", "output": "## Molecular Property Analysis: ANAGRELIDE\n\n### Structure\n```\nO=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 256.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.93 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 44.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.770\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 816.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 133.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 816.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 133.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1\nCandidate Name: PKI-166\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 330.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1\nCandidate Name: PKI-166", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 330.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cl.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1\nDrug Name: ANTAZOLINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cl.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1\nDrug Name: ANTAZOLINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl\nName: FELODIPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl\nName: FELODIPINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: HEXOBARBITAL\n\n### Structure\n```\nCN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 236.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.20 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.550\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O", "output": "## Molecular Property Analysis: HEXOBARBITAL\n\n### Structure\n```\nCN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 236.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.20 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.550\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21\nName: R-1487 HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21\nName: R-1487 HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O\nHYDROFLUMETHIAZIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O\nHYDROFLUMETHIAZIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(N2CCCCC2)nn2cnnc12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 217.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(N2CCCCC2)nn2cnnc12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 217.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN1C(=O)c2ccccc2C1Nc1ccc(OCCN2CCCCC2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 365.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN1C(=O)c2ccccc2C1Nc1ccc(OCCN2CCCCC2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 365.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1\nDrug Name: TEGAVIVINT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 588.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 139.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1\nDrug Name: TEGAVIVINT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 588.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 139.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C1C[C@@]2(C(=O)N1)C(=O)N(Cc1ccc(Br)cc1F)C(=O)c1cccn12\nName: RANIRESTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C1C[C@@]2(C(=O)N1)C(=O)N(Cc1ccc(Br)cc1F)C(=O)c1cccn12\nName: RANIRESTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCc1cc(C(N)=S)ccn1\nPROTIONAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCc1cc(C(N)=S)ccn1\nPROTIONAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(CCCCCCCCCCCCC1CCCC1)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)CCCCCCCCCCCCC3CCCC3)cc2)cc1\nCandidate Name: CHAULMOSULFONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 777.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 14.14 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(CCCCCCCCCCCCC1CCCC1)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)CCCCCCCCCCCCC3CCCC3)cc2)cc1\nCandidate Name: CHAULMOSULFONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 777.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 14.14 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 823.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 823.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Brc1c(NC2=NCCN2)ccc2nccnc12\nCandidate Name: BRIMONIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 292.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Brc1c(NC2=NCCN2)ccc2nccnc12\nCandidate Name: BRIMONIDINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 292.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1Br\nCandidate Name: BROXURIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1Br\nCandidate Name: BROXURIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN1CCC(OC(c2ccccc2)c2ccccc2)CC1\nCandidate Name: DIPHENYLPYRALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN1CCC(OC(c2ccccc2)c2ccccc2)CC1\nCandidate Name: DIPHENYLPYRALINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1\nESREBOXETINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1\nESREBOXETINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nN=C(Nc1c([N+](=O)[O-])cnc2ccccc12)N1CCOCC1\nTROQUIDAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nN=C(Nc1c([N+](=O)[O-])cnc2ccccc12)N1CCOCC1\nTROQUIDAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccc(CCn2c3c(c4cc(Cl)ccc42)CN(C)CC3)cn1\nDORASTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 339.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccc(CCn2c3c(c4cc(Cl)ccc42)CN(C)CC3)cn1\nDORASTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 339.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)=CCOC(=O)c1ccccc1Nc1cccc(C(F)(F)F)c1\nPREFENAMATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 349.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)=CCOC(=O)c1ccccc1Nc1cccc(C(F)(F)F)c1\nPREFENAMATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 349.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C\nName: ETHINYL ESTRADIOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C\nName: ETHINYL ESTRADIOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc([N-]S(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1F.[Na+]\nCandidate Name: BATABULIN SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc([N-]S(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1F.[Na+]\nCandidate Name: BATABULIN SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(Oc1ccc(Cl)cc1)C(=O)OCCSCCCCCCCCCCSCCOC(=O)C(C)(C)Oc1ccc(Cl)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 687.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.68 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(Oc1ccc(Cl)cc1)C(=O)OCCSCCCCCCCCCCSCCOC(=O)C(C)(C)Oc1ccc(Cl)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 687.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.68 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O\nDrug Name: YOHIMBINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O\nDrug Name: YOHIMBINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccccc1[C@H](Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1\nCandidate Name: FIRSOCOSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 569.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccccc1[C@H](Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1\nCandidate Name: FIRSOCOSTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 569.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(NNC(=O)c1ccccc1)c1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(NNC(=O)c1ccccc1)c1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1(C)[C@@H](OC(=O)[C@H]2CCCC[C@H]2C(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12\nCICLOXOLONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 624.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1(C)[C@@H](OC(=O)[C@H]2CCCC[C@H]2C(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12\nCICLOXOLONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 624.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(CCN)cc(OC)c1OC\nName: MESCALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(CCN)cc(OC)c1OC\nName: MESCALINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(CCBr)N1CCN(C(=O)CCBr)CC1\nName: PIPOBROMAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(CCBr)N1CCN(C(=O)CCBr)CC1\nName: PIPOBROMAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC[N+](C)(C)CCN(C)CC[N+](C)(C)CC\nAZAMETHONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 231.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC[N+](C)(C)CCN(C)CC[N+](C)(C)CC\nAZAMETHONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 231.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CCCOC1(Cc2ccccc2)CCCCCC1\nBENCYCLANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CCCOC1(Cc2ccccc2)CCCCCC1\nBENCYCLANE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nOCCC1CCN(CC/C=C2/c3ccc(F)cc3Sc3ccc(C(F)(F)F)cc32)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 451.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.23 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nOCCC1CCN(CC/C=C2/c3ccc(F)cc3Sc3ccc(C(F)(F)F)cc32)CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 451.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.23 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1\nCandidate Name: ENROFLOXACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 359.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1\nCandidate Name: ENROFLOXACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 359.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)C(=O)CCn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccncc1\nDrug Name: JNJ-39393406\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)C(=O)CCn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccncc1\nDrug Name: JNJ-39393406", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc(N)c(Br)cc1C(=O)NC1CCN(Cc2ccc(Cl)cc2)CC1\nBROCLEPRIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc(N)c(Br)cc1C(=O)NC1CCN(Cc2ccc(Cl)cc2)CC1\nBROCLEPRIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=S(=O)(O)CI\nCandidate Name: METHIODAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 222.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=S(=O)(O)CI\nCandidate Name: METHIODAL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 222.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23\nC-1311\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 350.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23\nC-1311", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 350.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1c(Cl)cc([C@@H](O)CNCCCCCCOCCc2ccccn2)cc1Cl\nDrug Name: PICUMETEROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 426.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1c(Cl)cc([C@@H](O)CNCCCCCCOCCc2ccccn2)cc1Cl\nDrug Name: PICUMETEROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 426.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)Cc1ccc(C(C)C(=O)O)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: IBUPROFEN\n\n### Structure\n```\nCC(C)Cc1ccc(C(C)C(=O)O)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 206.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.07 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.820\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)Cc1ccc(C(C)C(=O)O)cc1", "output": "## Molecular Property Analysis: IBUPROFEN\n\n### Structure\n```\nCC(C)Cc1ccc(C(C)C(=O)O)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 206.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.07 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.820\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 340.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 340.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)C1c2ccccc2CCc2ccccc21\nDrug Name: CYHEPTAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 237.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)C1c2ccccc2CCc2ccccc21\nDrug Name: CYHEPTAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 237.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O\nCandidate Name: DOXYLAMINE SUCCINATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 388.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O\nCandidate Name: DOXYLAMINE SUCCINATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 388.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ETIDOCAINE\n\n### Structure\n```\nCCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 276.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.75 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 32.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.820\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C", "output": "## Molecular Property Analysis: ETIDOCAINE\n\n### Structure\n```\nCCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 276.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.75 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 32.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.820\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1\nFLUPHENAZINE DECANOATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 591.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1\nFLUPHENAZINE DECANOATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 591.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCNc1c2c(nc3ccccc13)CCCC2\nName: BUCRICAINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCNc1c2c(nc3ccccc13)CCCC2\nName: BUCRICAINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC1(c2ccncc2)CCC(=O)NC1=O\nCandidate Name: ROGLETIMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 218.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC1(c2ccncc2)CCC(=O)NC1=O\nCandidate Name: ROGLETIMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 218.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCC/N=C1\\S/C(=C\\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C\nPONESIMOD\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCC/N=C1\\S/C(=C\\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C\nPONESIMOD", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[N+]1(CC2COC(c3ccccc3)(C3CCCCC3)O2)CCCCC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 18.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[N+]1(CC2COC(c3ccccc3)(C3CCCCC3)O2)CCCCC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 18.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)OCC(=O)Nc1cc(C#N)cc(NC(=O)COC(C)=O)c1Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 367.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)OCC(=O)Nc1cc(C#N)cc(NC(=O)COC(C)=O)c1Cl", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 367.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C\nDrug Name: GABAPENTIN ENACARBIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C\nDrug Name: GABAPENTIN ENACARBIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C#CCOC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1\nDrug Name: PARGEVERINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C#CCOC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1\nDrug Name: PARGEVERINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO\nCandidate Name: DEXAMETHASONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 392.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO\nCandidate Name: DEXAMETHASONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 392.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O\nTRIFLUSAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O\nTRIFLUSAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O\nCandidate Name: AZD1386\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 423.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O\nCandidate Name: AZD1386", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 423.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(OCc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)O\nName: CLOBUZARIT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 304.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(OCc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)O\nName: CLOBUZARIT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 304.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)c1ccccc1O.c1c[nH]cn1\nIMIDAZOLE SALICYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 206.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)c1ccccc1O.c1c[nH]cn1\nIMIDAZOLE SALICYLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 206.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=P([O-])([O-])O.[Na+].[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 142.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=P([O-])([O-])O.[Na+].[Na+]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 142.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nN[C@H](CC(=O)O)C(=O)O\nD-ASPARTATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 133.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nN[C@H](CC(=O)O)C(=O)O\nD-ASPARTATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 133.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)[C@H](N)c4ccc(O)cc4)[C@H]3SC2)s1\nCEFAPAROLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 493.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 158.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)[C@H](N)c4ccc(O)cc4)[C@H]3SC2)s1\nCEFAPAROLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 493.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 158.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC1CCC2(CC1)N=C(N)N=C(N)N2c1ccc(Cl)cc1\nDrug Name: SPIROTRIAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC1CCC2(CC1)N=C(N)N=C(N)N2c1ccc(Cl)cc1\nDrug Name: SPIROTRIAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1\nCandidate Name: ANAGLIPTIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1\nCandidate Name: ANAGLIPTIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCn1c(=O)c2ccccc2n2c(CN3CCCCC3)nnc12\nName: BINIZOLAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCn1c(=O)c2ccccc2n2c(CN3CCCCC3)nnc12\nName: BINIZOLAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN[C@@H](C)[C@@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1\nCandidate Name: PREMAFLOXACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 403.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN[C@@H](C)[C@@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1\nCandidate Name: PREMAFLOXACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 403.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC(NC(C)C)C(O)c1ccc(O)c(O)c1\nCandidate Name: ISOETHARINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 239.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC(NC(C)C)C(O)c1ccc(O)c(O)c1\nCandidate Name: ISOETHARINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 239.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)COc2ccc(OC)cc2)[C@@H]1OC\nMEFESERPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 578.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 108.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)COc2ccc(OC)cc2)[C@@H]1OC\nMEFESERPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 578.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 108.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cccc(OC2CCNCC2O)c1C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 221.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cccc(OC2CCNCC2O)c1C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 221.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3cc(-c4ccc5[nH]c([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc3c2)c[nH]1)C(C)C.Cl.Cl\nDrug Name: RAVIDASVIR HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 835.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 174.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3cc(-c4ccc5[nH]c([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc3c2)c[nH]1)C(C)C.Cl.Cl\nDrug Name: RAVIDASVIR HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 835.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 174.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1\nCandidate Name: RILPIVIRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1\nCandidate Name: RILPIVIRINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCNC1=NC(=O)C(c2ccccc2)O1\nCandidate Name: FENOZOLONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 204.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCNC1=NC(=O)C(c2ccccc2)O1\nCandidate Name: FENOZOLONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 204.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)Cn1nc(-c2ccccc2)c(-c2ccccc2)c1CC(=O)O\nCandidate Name: BUFEZOLAC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)Cn1nc(-c2ccccc2)c(-c2ccccc2)c1CC(=O)O\nCandidate Name: BUFEZOLAC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nc1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1\nName: ARUNDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 31.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nc1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1\nName: ARUNDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 31.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCc1c(-c2ccccc2)[nH]n(C2CCN(C)CC2)c1=O\nPIPERYLONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCc1c(-c2ccccc2)[nH]n(C2CCN(C)CC2)c1=O\nPIPERYLONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1\nDrug Name: PF-03715455\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 700.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.80 | ‚ö† High (>5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 129.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1\nDrug Name: PF-03715455", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 700.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.80 | ‚ö† High (>5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 129.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)OC(C)(C)C\nDrug Name: Semagacestat\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)OC(C)(C)C\nDrug Name: Semagacestat", "output": "## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CCOC(c1ccccc1)c1ccc(Br)cc1.Cl\nBROMODIPHENHYDRAMINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CCOC(c1ccccc1)c1ccc(Br)cc1.Cl\nBROMODIPHENHYDRAMINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(/C=C(\\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 665.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 138.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(/C=C(\\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 665.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 138.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCNCC(O)c1cccc(OC(=O)C(C)(C)C)c1\nName: ETILEFRINE PIVALATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCNCC(O)c1cccc(OC(=O)C(C)(C)C)c1\nName: ETILEFRINE PIVALATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(C(=O)Nc2cc(Nc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)ccc2F)n(C)n1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 467.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(C(=O)Nc2cc(Nc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)ccc2F)n(C)n1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 467.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC#CCC1(OC(N)=O)CCCCC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 181.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC#CCC1(OC(N)=O)CCCCC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 181.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1\nName: DARIFENACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 426.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1\nName: DARIFENACIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 426.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nN=C(N)NCCC[C@H](N)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O\nName: ARGININE GLUTAMATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nN=C(N)NCCC[C@H](N)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O\nName: ARGININE GLUTAMATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nN=C(N)N/N=C/c1c(Cl)cccc1Cl\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: GUANABENZ\n\n### Structure\n```\nN=C(N)N/N=C/c1c(Cl)cccc1Cl\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 231.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.81 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 74.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.410\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nN=C(N)N/N=C/c1c(Cl)cccc1Cl", "output": "## Molecular Property Analysis: GUANABENZ\n\n### Structure\n```\nN=C(N)N/N=C/c1c(Cl)cccc1Cl\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 231.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.81 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 74.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.410\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCC(=O)C1c2cccc(O)c2C(=O)c2c(O)cccc21\nName: BUTANTRONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCC(=O)C1c2cccc(O)c2C(=O)c2c(O)cccc21\nName: BUTANTRONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1c(S(=O)(=O)[O-])oc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C.[Na+]\nName: SODIUM TANSHINONE IIA SULFONATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1c(S(=O)(=O)[O-])oc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C.[Na+]\nName: SODIUM TANSHINONE IIA SULFONATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nS=P(N1CC1)(N1CC1)N1CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: THIOTEPA\n\n### Structure\n```\nS=P(N1CC1)(N1CC1)N1CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 189.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.16 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 9.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.460\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nS=P(N1CC1)(N1CC1)N1CC1", "output": "## Molecular Property Analysis: THIOTEPA\n\n### Structure\n```\nS=P(N1CC1)(N1CC1)N1CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 189.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.16 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 9.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.460\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nN[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 235.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nN[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 235.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)Nc1cnn2c(C)nc3ccccc3c12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)Nc1cnn2c(C)nc3ccccc3c12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COC1=C(OC)C(=O)C(C/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CCC=C(C)C)=C(C)C1=O\nCandidate Name: UBIDECARENONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 863.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 17.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COC1=C(OC)C(=O)C(C/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CC/C=C(\\C)CCC=C(C)C)=C(C)C1=O\nCandidate Name: UBIDECARENONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 863.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 17.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCCN1CCCCC1)c1ccc(F)cc1\nDrug Name: PRIMAPERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCCN1CCCCC1)c1ccc(F)cc1\nDrug Name: PRIMAPERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\\C(=O)O\nDEXBROMPHENIRAMINE MALEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 435.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\\C(=O)O\nDEXBROMPHENIRAMINE MALEATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 435.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCC[C@@H](O)/C=C(C)/C=C/C=C/C(=O)N1CCCC1=O\nName: PECILOCIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 291.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCC[C@@H](O)/C=C(C)/C=C/C=C/C(=O)N1CCCC1=O\nName: PECILOCIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 291.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(NCCCCCCN2CCN(CCC(C)O)CC2)c2ncccc2c1\nName: MOXIPRAQUINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 414.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(NCCCCCCN2CCN(CCC(C)O)CC2)c2ncccc2c1\nName: MOXIPRAQUINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 414.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: SPIRAPRIL\n\n### Structure\n```\nCCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 466.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.39 | 0-5 | ‚úì |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 95.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2", "output": "## Molecular Property Analysis: SPIRAPRIL\n\n### Structure\n```\nCCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 466.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.39 | 0-5 | ‚úì |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 95.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1.[Br-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 412.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1.[Br-]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 412.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN1CCC23CCCCC2C1Cc1ccc(O)cc13\nName: RACEMORPHAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN1CCC23CCCCC2C1Cc1ccc(O)cc13\nName: RACEMORPHAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)NS(=O)(=O)c1cc(N)ccc1S(=O)(=O)c1ccc(N)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 149.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)NS(=O)(=O)c1cc(N)ccc1S(=O)(=O)c1ccc(N)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 149.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1.O=P(O)(O)O\nDrug Name: OSELTAMIVIR PHOSPHATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 410.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1.O=P(O)(O)O\nDrug Name: OSELTAMIVIR PHOSPHATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 410.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2\nNADOLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2\nNADOLOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC1(O)CCN2CCc3ccc(C)cc3C2C1\nCandidate Name: TOLQUINZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 245.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC1(O)CCN2CCc3ccc(C)cc3C2C1\nCandidate Name: TOLQUINZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 245.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2\nName: VINORELBINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 779.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 133.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2\nName: VINORELBINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 779.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 133.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1\nName: PROBUCOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 516.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.91 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1\nName: PROBUCOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 516.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.91 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl\nName: BENZYDAMINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl\nName: BENZYDAMINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCOCCOC(=O)c1nc2cc(Cl)ccc2o1\nCandidate Name: ECLAZOLAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 269.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCOCCOC(=O)c1nc2cc(Cl)ccc2o1\nCandidate Name: ECLAZOLAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 269.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Cn1ccnc1)c1ccc2ccccc2c1\nDrug Name: NAFIMIDONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Cn1ccnc1)c1ccc2ccccc2c1\nDrug Name: NAFIMIDONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Oc1noc2c1CCNC2\nCandidate Name: GABOXADOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 140.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Oc1noc2c1CCNC2\nCandidate Name: GABOXADOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 140.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCC(O)/C=C/C1C(O)CC2N=C(SCCCC(=O)OC)CC21\nTILSUPROST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCC(O)/C=C/C1C(O)CC2N=C(SCCCC(=O)OC)CC21\nTILSUPROST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNC(=O)c1csc([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 260.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNC(=O)c1csc([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 260.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TOLAMOLOL\n\n### Structure\n```\nCc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 344.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.50 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 93.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.570\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1", "output": "## Molecular Property Analysis: TOLAMOLOL\n\n### Structure\n```\nCc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 344.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.50 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 93.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.570\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1\nDrug Name: ZALCITABINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1\nDrug Name: ZALCITABINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)Nc1nc2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1\nDrug Name: AMG-517\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 430.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)Nc1nc2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1\nDrug Name: AMG-517", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 430.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1\nENTRECTINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 560.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1\nENTRECTINIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 560.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[N+](C)(CCOc1ccccc1)Cc1cccs1.O=S(=O)([O-])c1ccc(Cl)cc1\nCandidate Name: THENIUM CLOSYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[N+](C)(CCOc1ccccc1)Cc1cccs1.O=S(=O)([O-])c1ccc(Cl)cc1\nCandidate Name: THENIUM CLOSYLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC[N+](CC)(CCOc1ccc(CC(C)(C)CC(C)C)cc1)Cc1ccccc1\nOCTAFONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC[N+](CC)(CCOc1ccc(CC(C)(C)CC(C)C)cc1)Cc1ccccc1\nOCTAFONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nO=C1c2ccccc2C(=O)C1c1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PHENINDIONE\n\n### Structure\n```\nO=C1c2ccccc2C(=O)C1c1ccccc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 222.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.85 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 34.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.700\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nO=C1c2ccccc2C(=O)C1c1ccccc1", "output": "## Molecular Property Analysis: PHENINDIONE\n\n### Structure\n```\nO=C1c2ccccc2C(=O)C1c1ccccc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 222.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.85 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 34.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.700\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)=CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 320.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)=CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 320.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)/C=C/c1ccc(O)c(O)c1\nCandidate Name: CAFFEIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)/C=C/c1ccc(O)c(O)c1\nCandidate Name: CAFFEIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN1CCC(C(=O)N2c3ccccc3NC(=O)c3cccnc32)CC1\nCandidate Name: NUVENZEPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 336.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN1CCC(C(=O)N2c3ccccc3NC(=O)c3cccnc32)CC1\nCandidate Name: NUVENZEPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 336.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1cc(-c2ccccc2)n[n+](CCCC(=O)O)c1N.[Cl-]\nFAMIRAPRINIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1cc(-c2ccccc2)n[n+](CCCC(=O)O)c1N.[Cl-]\nFAMIRAPRINIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ATEVIRDINE MESYLATE\n\n### Structure\n```\nCCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 379.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.97 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 73.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.710\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1", "output": "## Molecular Property Analysis: ATEVIRDINE MESYLATE\n\n### Structure\n```\nCCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 379.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.97 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 73.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.710\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nC[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TIXANOX\n\n### Structure\n```\nC[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 302.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.38 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 90.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.580\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nC[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1", "output": "## Molecular Property Analysis: TIXANOX\n\n### Structure\n```\nC[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 302.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.38 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 90.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.580\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@@]1(CC(=O)O)OC[C@H](Cc2ccccc2)c2c1[nH]c1ccccc21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 349.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@@]1(CC(=O)O)OC[C@H](Cc2ccccc2)c2c1[nH]c1ccccc21", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 349.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1.Cl\nCandidate Name: EPIRUBICIN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 580.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 206.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1.Cl\nCandidate Name: EPIRUBICIN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 580.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 206.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=[N+]([O-])OC[C@@H](O[N+](=O)[O-])[C@@H](O[N+](=O)[O-])[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]\nMANNITOL HEXANITRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 314.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=[N+]([O-])OC[C@@H](O[N+](=O)[O-])[C@@H](O[N+](=O)[O-])[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]\nMANNITOL HEXANITRATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 314.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cc(C)[n+]([N-]C(=O)c2ccc(Cl)c(S(N)(=O)=O)c2)c(C)c1\nName: BESULPAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cc(C)[n+]([N-]C(=O)c2ccc(Cl)c(S(N)(=O)=O)c2)c(C)c1\nName: BESULPAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOC(=O)CCCCC(CCSS/C(CCO)=C(/C)N(C=O)Cc1cnc(C)nc1N)SC(C)=O\nOCTOTIAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 544.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOC(=O)CCCCC(CCSS/C(CCO)=C(/C)N(C=O)Cc1cnc(C)nc1N)SC(C)=O\nOCTOTIAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 544.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13)c1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13)c1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCCCCCCCCCCCCCCCO\nDrug Name: DOCOSANOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.80 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCCCCCCCCCCCCCCCO\nDrug Name: DOCOSANOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.80 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C=C[C@@H]1CNCC[C@H]1CCCc1ccnc2ccc(OC)cc12\nCandidate Name: IVOQUALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C=C[C@@H]1CNCC[C@H]1CCCc1ccnc2ccc(OC)cc12\nCandidate Name: IVOQUALINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1(C)C(=O)N(C(=O)NCC2CCN(CC3(O)CCOCC3)CC2)c2cc(F)ccc21\nName: PF-03382792\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 433.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1(C)C(=O)N(C(=O)NCC2CCN(CC3(O)CCOCC3)CC2)c2cc(F)ccc21\nName: PF-03382792", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 433.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)S(=O)(=O)n1c(N)nc2ccc(/C(=N/O)c3ccccc3)cc21\nENVIROXIME\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)S(=O)(=O)n1c(N)nc2ccc(/C(=N/O)c3ccccc3)cc21\nENVIROXIME", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1nc2c(c(=O)[nH]1)N1CN(c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)C[C@H]1CN2\nARFOLITIXORIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 194.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1nc2c(c(=O)[nH]1)N1CN(c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)C[C@H]1CN2\nARFOLITIXORIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 194.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21\nTAK-733\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 504.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21\nTAK-733", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 504.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)N1c2ccccc2Sc2ccccc21\nName: FENOVERINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 459.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)N1c2ccccc2Sc2ccccc21\nName: FENOVERINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 459.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCn1cc(C(=O)O)c(=O)c2ccc(C)nc21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 232.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCn1cc(C(=O)O)c(=O)c2ccc(C)nc21", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 232.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)C(=O)C1(c2ccccc2)CC1CN\nDrug Name: MILNACIPRAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)C(=O)C1(c2ccccc2)CC1CN\nDrug Name: MILNACIPRAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(Nc1ccccc1)c1cc(Br)cc(Br)c1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(Nc1ccccc1)c1cc(Br)cc(Br)c1O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5\nCandidate Name: NALFURAFINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 476.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5\nCandidate Name: NALFURAFINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 476.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nNc1cc[nH]c(=O)n1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CYTOSINE\n\n### Structure\n```\nNc1cc[nH]c(=O)n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 111.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.65 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 71.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nNc1cc[nH]c(=O)n1", "output": "## Molecular Property Analysis: CYTOSINE\n\n### Structure\n```\nNc1cc[nH]c(=O)n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 111.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.65 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 71.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)N1CCN(c2ccc(N3CCN(c4ccc(OC[C@H]5OC[C@](Cn6cncn6)(c6ccc(F)cc6F)O5)cc4)CC3)cc2)C1=O\nName: PRAMICONAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 659.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)N1CCN(c2ccc(N3CCN(c4ccc(OC[C@H]5OC[C@](Cn6cncn6)(c6ccc(F)cc6F)O5)cc4)CC3)cc2)C1=O\nName: PRAMICONAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 659.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCO[C@@H]1[C@H](OP(=O)(S)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2O)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O\nName: INARIGIVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 587.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 228.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCO[C@@H]1[C@H](OP(=O)(S)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2O)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O\nName: INARIGIVIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 587.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 228.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O\nCandidate Name: ITX-5061 FREE BASE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 583.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 123.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O\nCandidate Name: ITX-5061 FREE BASE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 583.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 123.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)n1cc(C#N)c2cc(-n3cc(C(=O)O)cn3)ccc21\nTIGULIXOSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 294.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)n1cc(C#N)c2cc(-n3cc(C(=O)O)cn3)ccc21\nTIGULIXOSTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 294.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1\nName: NIVOCASAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1\nName: NIVOCASAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nOc1ccc2c(c1)C(Cc1c[nH]cn1)CC2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nOc1ccc2c(c1)C(Cc1c[nH]cn1)CC2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@@H]1Cc2cc(O)ccc2[C@H]2CC[C@]3(C)C(=O)CC[C@H]3[C@H]12\nName: ALMESTRONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@@H]1Cc2cc(O)ccc2[C@H]2CC[C@]3(C)C(=O)CC[C@H]3[C@H]12\nName: ALMESTRONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nN[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nN[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)CCCNc1nccc2c(C)c3[nH]c4ccc(OC)cc4c3c(C)c12\nDrug Name: RETELLIPTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.64 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)CCCNc1nccc2c(C)c3[nH]c4ccc(OC)cc4c3c(C)c12\nDrug Name: RETELLIPTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.64 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNC(=O)Oc1ccc(Cc2ccccc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 227.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNC(=O)Oc1ccc(Cc2ccccc2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 227.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=P([O-])([O-])O.[K+].[K+]\nName: POTASSIUM PHOSPHATE, DIBASIC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 174.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=P([O-])([O-])O.[K+].[K+]\nName: POTASSIUM PHOSPHATE, DIBASIC", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 174.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 385.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 385.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F\nCandidate Name: BELZUTIFAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F\nCandidate Name: BELZUTIFAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nNCCNCCNCCN\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TRIENTINE\n\n### Structure\n```\nNCCNCCNCCN\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 146.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -1.92 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 76.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.320\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nNCCNCCNCCN", "output": "## Molecular Property Analysis: TRIENTINE\n\n### Structure\n```\nNCCNCCNCCN\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 146.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -1.92 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 76.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.320\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)OC(=O)CCC/C=C\\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O\nDrug Name: TAFLUPROST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)OC(=O)CCC/C=C\\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O\nDrug Name: TAFLUPROST", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)Nc1c(I)c(C(=O)[O-])c(I)c(N(C)C(C)=O)c1I.CC(=O)Nc1c(I)c(C(=O)[O-])c(I)c(N(C)C(C)=O)c1I.[Mg+2]\nDrug Name: METRIZOATE MAGNESIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1278.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)Nc1c(I)c(C(=O)[O-])c(I)c(N(C)C(C)=O)c1I.CC(=O)Nc1c(I)c(C(=O)[O-])c(I)c(N(C)C(C)=O)c1I.[Mg+2]\nDrug Name: METRIZOATE MAGNESIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1278.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(O)c1ccccc1-c1ccc(C(F)(F)F)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 266.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(O)c1ccccc1-c1ccc(C(F)(F)F)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 266.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)c1cccc(C(C)C)c1OCOP(=O)([O-])[O-].[Na+].[Na+]\nDrug Name: FOSPROPOFOL DISODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)c1cccc(C(C)C)c1OCOP(=O)([O-])[O-].[Na+].[Na+]\nDrug Name: FOSPROPOFOL DISODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(OC(C)C)O[C@H]2[C@@]1(C)F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 431.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(OC(C)C)O[C@H]2[C@@]1(C)F", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 431.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1cc(/C=C2\\CCC/C(=C\\c3ccc(O)c(OC)c3)C2=O)ccc1O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CYCLOVALONE\n\n### Structure\n```\nCOc1cc(/C=C2\\CCC/C(=C\\c3ccc(O)c(OC)c3)C2=O)ccc1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 366.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.34 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 76.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.790\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1cc(/C=C2\\CCC/C(=C\\c3ccc(O)c(OC)c3)C2=O)ccc1O", "output": "## Molecular Property Analysis: CYCLOVALONE\n\n### Structure\n```\nCOc1cc(/C=C2\\CCC/C(=C\\c3ccc(O)c(OC)c3)C2=O)ccc1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 366.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.34 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 76.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.790\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(C)/C=N/c1c(I)cc(I)c(CCC(=O)[O-])c1I.[Na+]\nName: IPODATE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 619.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(C)/C=N/c1c(I)cc(I)c(CCC(=O)[O-])c1I.[Na+]\nName: IPODATE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 619.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCCNC(=N)NC(=N)N\nPOLIHEXANIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 185.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCCNC(=N)NC(=N)N\nPOLIHEXANIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 185.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)COc1ccccc1NC(=O)c1ccc(Cl)c(Cl)c1\nName: CLAMIDOXIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 340.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)COc1ccccc1NC(=O)c1ccc(Cl)c(Cl)c1\nName: CLAMIDOXIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 340.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(/C=C/C(=O)NCCCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)cn1\nCandidate Name: TAGORIZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 468.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(/C=C/C(=O)NCCCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)cn1\nCandidate Name: TAGORIZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 468.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNCC(O)CC12CCC(c3ccccc31)c1ccccc12\nOXAPROTILINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 293.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNCC(O)CC12CCC(c3ccccc31)c1ccccc12\nOXAPROTILINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 293.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1cc(O)c(C(C)C)cc1/N=N/c1ccc(S(=O)(=O)c2ccc(/N=N/c3cc(C(C)C)c(O)cc3C)cc2)cc1\nDIATHYMOSULFONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 570.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.63 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 124.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1cc(O)c(C(C)C)cc1/N=N/c1ccc(S(=O)(=O)c2ccc(/N=N/c3cc(C(C)C)c(O)cc3C)cc2)cc1\nDIATHYMOSULFONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 570.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.63 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 124.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)Cn1c(C(=O)Nc2nc(-c3ccccc3Cl)cs2)cc2ccccc21\nCandidate Name: LINTITRIPT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)Cn1c(C(=O)Nc2nc(-c3ccccc3Cl)cs2)cc2ccccc21\nCandidate Name: LINTITRIPT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(NCCN1CCN(c2cccc3c2OC[C@H](CO)O3)CC1)c1ccc(F)cc1\nName: FLESINOXAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(NCCN1CCN(c2cccc3c2OC[C@H](CO)O3)CC1)c1ccc(F)cc1\nName: FLESINOXAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCC(Cc1c(I)cc(I)c(N2CCCC2=O)c1I)C(=O)O\nDrug Name: IOLIDONIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 639.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCC(Cc1c(I)cc(I)c(N2CCCC2=O)c1I)C(=O)O\nDrug Name: IOLIDONIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 639.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@H](c2cccs2)CN(CC(=O)O)C1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 476.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@H](c2cccs2)CN(CC(=O)O)C1=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 476.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nO=C(O)Cn1c(=O)n(Cc2ccc(Br)cc2F)c(=O)c2ccc(Cl)cc21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ZENARESTAT\n\n### Structure\n```\nO=C(O)Cn1c(=O)n(Cc2ccc(Br)cc2F)c(=O)c2ccc(Cl)cc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 441.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.85 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 81.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.680\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nO=C(O)Cn1c(=O)n(Cc2ccc(Br)cc2F)c(=O)c2ccc(Cl)cc21", "output": "## Molecular Property Analysis: ZENARESTAT\n\n### Structure\n```\nO=C(O)Cn1c(=O)n(Cc2ccc(Br)cc2F)c(=O)c2ccc(Cl)cc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 441.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.85 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 81.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.680\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC.Cl\nName: PAPAVERINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC.Cl\nName: PAPAVERINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C[C@H]3C[C@@H]12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 414.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 161.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C[C@H]3C[C@@H]12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 414.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 161.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 362.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 362.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCCCCCCCCS[C@H](C(=O)Nc1cc(C)c(O)c(C)c1C)c1ccccc1\nEFLUCIMIBE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 469.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.65 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCCCCCCCCS[C@H](C(=O)Nc1cc(C)c(O)c(C)c1C)c1ccccc1\nEFLUCIMIBE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 469.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.65 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 348.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 348.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CC=C4C=C(OC5CCCC5)CC[C@@H]4[C@H]3CC[C@@]21C\nDrug Name: QUINGESTANOL ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.95 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CC=C4C=C(OC5CCCC5)CC[C@@H]4[C@H]3CC[C@@]21C\nDrug Name: QUINGESTANOL ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.95 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COCC(O)COC(C)(C)C\nDrug Name: TERBUPROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 162.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COCC(O)COC(C)(C)C\nDrug Name: TERBUPROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 162.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(I)C1OCC(CO)O1\nGLYCEROL, IODINATED\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 258.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(I)C1OCC(CO)O1\nGLYCEROL, IODINATED", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 258.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nOc1ccc(C(O)CNC2CCC2)cc1O\nNORBUDRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 223.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nOc1ccc(C(O)CNC2CCC2)cc1O\nNORBUDRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 223.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21\nDrug Name: MEDAZEPAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21\nDrug Name: MEDAZEPAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(N)C12CC3CC(CC(C3)C1)C2\nCandidate Name: RIMANTADINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 179.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(N)C12CC3CC(CC(C3)C1)C2\nCandidate Name: RIMANTADINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 179.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ALDOSTERONE\n\n### Structure\n```\nC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 360.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.85 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 91.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.750\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12", "output": "## Molecular Property Analysis: ALDOSTERONE\n\n### Structure\n```\nC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 360.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.85 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 91.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.750\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1\nDrug Name: HALOPERIDOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1\nDrug Name: HALOPERIDOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1NC(=O)COC1c1ccccc1\nCandidate Name: FENMETRAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 191.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1NC(=O)COC1c1ccccc1\nCandidate Name: FENMETRAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 191.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1\nDrug Name: LEVOMETHADYL ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1\nDrug Name: LEVOMETHADYL ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)C[C@H](CN)CC(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 159.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)C[C@H](CN)CC(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 159.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=c1oc(CCN2CCN(c3ccccc3)CC2)c(-c2ccc(Cl)cc2)o1\nCandidate Name: CLODOXOPONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=c1oc(CCN2CCN(c3ccccc3)CC2)c(-c2ccc(Cl)cc2)o1\nCandidate Name: CLODOXOPONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]\nName: DIVALPROEX SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]\nName: DIVALPROEX SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F\nVX-702\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 102.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F\nVX-702", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 102.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1\nDrug Name: TARANABANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 516.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1\nDrug Name: TARANABANT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 516.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 527.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 527.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O\nERIBULIN MESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 826.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O\nERIBULIN MESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 826.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2\nDrug Name: SITAXENTAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2\nDrug Name: SITAXENTAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCOCCOC(=O)C(c1ccccc1)N1CCCCC1\nDrug Name: BUTOPIPRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 319.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCOCCOC(=O)C(c1ccccc1)N1CCCCC1\nDrug Name: BUTOPIPRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 319.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)N(C(C)=O)c3ccccc32)cc1\nCandidate Name: TRIACETYLDIPHENOLISATIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)N(C(C)=O)c3ccccc32)cc1\nCandidate Name: TRIACETYLDIPHENOLISATIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1\nDrug Name: FURAZOLIDONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 225.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1\nDrug Name: FURAZOLIDONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 225.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc(CC(=O)Nc2ccccc2)cc1\nDrug Name: Compound_EXP005\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc(CC(=O)Nc2ccccc2)cc1\nDrug Name: Compound_EXP005", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCC(=O)O[C@]1(C(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nRESOCORTOL BUTYRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 430.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCC(=O)O[C@]1(C(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nRESOCORTOL BUTYRATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 430.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1\nCandidate Name: ODANACATIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 525.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1\nCandidate Name: ODANACATIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 525.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21\nCandidate Name: TENOFOVIR EXALIDEX\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 569.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21\nCandidate Name: TENOFOVIR EXALIDEX", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 569.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PYRONARIDINE\n\n### Structure\n```\nCOc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 518.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 6.09 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 73.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.230\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1", "output": "## Molecular Property Analysis: PYRONARIDINE\n\n### Structure\n```\nCOc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 518.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 6.09 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 73.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.230\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-]\nCLORAZEPATE DIPOTASSIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-]\nCLORAZEPATE DIPOTASSIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)c1ccc2c(c1)CC[C@H]2NC(=O)Nc1cccc2[nH]ncc12\nName: ABT-102\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 348.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)c1ccc2c(c1)CC[C@H]2NC(=O)Nc1cccc2[nH]ncc12\nName: ABT-102", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 348.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNCCCC[C@H](OP(=O)(O)CCCCc1ccccc1)C(=O)N1CCC[C@H]1C(=O)O\nCERONAPRIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 440.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNCCCC[C@H](OP(=O)(O)CCCCc1ccccc1)C(=O)N1CCC[C@H]1C(=O)O\nCERONAPRIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 440.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nC=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: BEVIRIMAT\n\n### Structure\n```\nC=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 584.8 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 8.14 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 100.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.240\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nC=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12", "output": "## Molecular Property Analysis: BEVIRIMAT\n\n### Structure\n```\nC=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 584.8 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 8.14 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 100.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.240\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1\nSOTALOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1\nSOTALOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12\nCandidate Name: CEBRANOPADOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 378.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.11 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12\nCandidate Name: CEBRANOPADOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 378.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.11 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1sc2ccccc2c1CC1=NCCN1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 230.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1sc2ccccc2c1CC1=NCCN1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 230.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1\nTIXANOX\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1\nTIXANOX", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TABIMORELIN\n\n### Structure\n```\nCNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 528.7 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 3.71 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 95.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.370\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N", "output": "## Molecular Property Analysis: TABIMORELIN\n\n### Structure\n```\nCNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 528.7 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 3.71 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 95.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.370\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1\nName: PRANLUKAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 481.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 123.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1\nName: PRANLUKAST", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 481.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 123.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC1(C)C=C(n2ccccc2=O)c2cc(C#N)ccc2O1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 278.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC1(C)C=C(n2ccccc2=O)c2cc(C#N)ccc2O1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 278.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]\nName: TRYPAN BLUE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 960.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]\nName: TRYPAN BLUE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 960.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MEDROXYPROGESTERONE ACETATE\n\n### Structure\n```\nCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 386.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.66 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 60.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.650\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C", "output": "## Molecular Property Analysis: MEDROXYPROGESTERONE ACETATE\n\n### Structure\n```\nCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 386.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.66 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 60.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.650\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O\nCandidate Name: BREQUINAR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O\nCandidate Name: BREQUINAR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PERGOLIDE\n\n### Structure\n```\nCCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 314.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.27 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 19.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.910\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21", "output": "## Molecular Property Analysis: PERGOLIDE\n\n### Structure\n```\nCCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 314.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.27 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 19.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.910\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(NCCCC(C)N)c2ncccc2c1\nName: QUINOCIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 259.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(NCCCC(C)N)c2ncccc2c1\nName: QUINOCIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 259.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(CN(C)C)CN1c2ccccc2Sc2ccccc21\nDrug Name: METHYLPROMAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 298.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(CN(C)C)CN1c2ccccc2Sc2ccccc21\nDrug Name: METHYLPROMAZINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 298.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: RITANSERIN\n\n### Structure\n```\nCc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 477.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 5.48 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 37.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.380\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1", "output": "## Molecular Property Analysis: RITANSERIN\n\n### Structure\n```\nCc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 477.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 5.48 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 37.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.380\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNc1ccc(/N=N/c2ccccc2)c(N)n1\nName: PHENAZOPYRIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 213.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNc1ccc(/N=N/c2ccccc2)c(N)n1\nName: PHENAZOPYRIDINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 213.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 784.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 784.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\\F)c(=O)n1\nCandidate Name: TEZACITABINE ANHYDROUS\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\\F)c(=O)n1\nCandidate Name: TEZACITABINE ANHYDROUS", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CC1)CC3\nDrug Name: OXILORPHAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CC1)CC3\nDrug Name: OXILORPHAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC(=O)O[C@]1(C(=O)SCCl)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\nCandidate Name: CLOTICASONE PROPIONATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 517.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC(=O)O[C@]1(C(=O)SCCl)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\nCandidate Name: CLOTICASONE PROPIONATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 517.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 475.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 475.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CC(O)C(c1ccccc1)c1cccc(Cl)c1\nCandidate Name: CLEMEPROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CC(O)C(c1ccccc1)c1cccc(Cl)c1\nCandidate Name: CLEMEPROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)c1ccc(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1\nDrug Name: PICOTRIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 365.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)c1ccc(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1\nDrug Name: PICOTRIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 365.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 530.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.33 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 530.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.33 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)Cc1ccc(CSCCNC(=O)c2ccc[n+]([O-])c2)o1\nDrug Name: RAMIXOTIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)Cc1ccc(CSCCNC(=O)c2ccc[n+]([O-])c2)o1\nDrug Name: RAMIXOTIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2\nCandidate Name: GAMMA-TOCOPHEROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.53 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2\nCandidate Name: GAMMA-TOCOPHEROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.53 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOCc1c(C(=O)OC(C)C)ncc2[nH]c3cccc(Oc4ccc(Cl)cc4)c3c12\nName: GEDOCARNIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.87 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOCc1c(C(=O)OC(C)C)ncc2[nH]c3cccc(Oc4ccc(Cl)cc4)c3c12\nName: GEDOCARNIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.87 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO\nDrug Name: XYLOSE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 150.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO\nDrug Name: XYLOSE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 150.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CC(=O)Nc1c(C)cccc1C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 234.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CC(=O)Nc1c(C)cccc1C", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 234.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 985.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 20.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 288.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 985.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 20.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 288.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1nc(OCCc2ccc(Cl)cc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O\nSONEDENOSON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 421.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 148.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1nc(OCCc2ccc(Cl)cc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O\nSONEDENOSON", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 421.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 148.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MOPIDRALAZINE\n\n### Structure\n```\nCc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 273.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.61 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 55.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.920\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1", "output": "## Molecular Property Analysis: MOPIDRALAZINE\n\n### Structure\n```\nCc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 273.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.61 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 55.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.920\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)c1ncn2c1CN(C)C(=O)c1c(I)cccc1-2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)c1ncn2c1CN(C)C(=O)c1c(I)cccc1-2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc(/C=C/c2ccc(O)cc2)cc(OC)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 256.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc(/C=C/c2ccc(O)cc2)cc(OC)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 256.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(N[C@@H](Cc1ccccc1)[C@@H](O)C(=O)N1C[C@@H](O)[C@@H](O)C1)c1cc2cc(Cl)ccc2[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(N[C@@H](Cc1ccccc1)[C@@H](O)C(=O)N1C[C@@H](O)[C@@H](O)C1)c1cc2cc(Cl)ccc2[nH]1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1\nCandidate Name: TOLAZAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1\nCandidate Name: TOLAZAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1\nCandidate Name: EZLOPITANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1\nCandidate Name: EZLOPITANT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(/C(C)=C\\C(=O)O)c(OC)c1\nCandidate Name: DIMECROTIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 222.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(/C(C)=C\\C(=O)O)c(OC)c1\nCandidate Name: DIMECROTIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 222.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1nc(/C=C/c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1\nE-2212\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 480.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.29 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1nc(/C=C/c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1\nE-2212", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 480.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.29 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCC1(C)C(=O)Nc2ccc(C3=NNC(=O)CC3)cc21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: INDOLIDAN\n\n### Structure\n```\nCC1(C)C(=O)Nc2ccc(C3=NNC(=O)CC3)cc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 257.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.53 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 70.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCC1(C)C(=O)Nc2ccc(C3=NNC(=O)CC3)cc21", "output": "## Molecular Property Analysis: INDOLIDAN\n\n### Structure\n```\nCC1(C)C(=O)Nc2ccc(C3=NNC(=O)CC3)cc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 257.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.53 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 70.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCOc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: nan\n\n### Structure\n```\nCOc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 358.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.16 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 81.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.760\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCOc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1", "output": "## Molecular Property Analysis: nan\n\n### Structure\n```\nCOc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 358.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.16 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 81.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.760\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]\nCandidate Name: METHYLNALTREXONE BROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 436.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]\nCandidate Name: METHYLNALTREXONE BROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 436.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCl.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 347.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCl.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 347.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: NCCCCN\nCandidate Name: PUTRESCINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 88.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: NCCCCN\nCandidate Name: PUTRESCINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 88.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1\nDrug Name: DABRAFENIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 519.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.36 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1\nDrug Name: DABRAFENIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 519.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.36 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)CC[C@H](NP(=O)(O)OCCC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCNC(=O)c1ccc(F)cc1)C(=O)O)C(=O)O)C(=O)O\nCTT-1057\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 706.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 9.0 | ‚ö† High (>5) |\n| Polar Surface Area | 295.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)CC[C@H](NP(=O)(O)OCCC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCNC(=O)c1ccc(F)cc1)C(=O)O)C(=O)O)C(=O)O\nCTT-1057", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 706.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 9.0 | ‚ö† High (>5) |\n| Polar Surface Area | 295.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc2c(cc1OC)[C@H](c1cc(OC)c(OC)c(OC)c1)[N@@+](C)(CCCOC(=O)/C=C(\\Cl)C(=O)OCCC[N@+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 993.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.84 | ‚ö† High (>5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 144.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc2c(cc1OC)[C@H](c1cc(OC)c(OC)c(OC)c1)[N@@+](C)(CCCOC(=O)/C=C(\\Cl)C(=O)OCCC[N@+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 993.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.84 | ‚ö† High (>5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 144.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl\nCandidate Name: LEVOCABASTINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl\nCandidate Name: LEVOCABASTINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1\nTALAZOPARIB TOSYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 552.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1\nTALAZOPARIB TOSYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 552.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]\nGLYCOPYRRONIUM BROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 398.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]\nGLYCOPYRRONIUM BROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 398.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OCC(=O)O)c(C(C)(C)C)c1\nName: CAMOBUCOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 574.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.67 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OCC(=O)O)c(C(C)(C)C)c1\nName: CAMOBUCOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 574.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.67 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCl.Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl\nName: AMITIFADINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCl.Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl\nName: AMITIFADINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc([N-]S(=O)(=O)c2ccc(N)cc2)nc(OC)n1.[Na+]\nSULFADIMETHOXINE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc([N-]S(=O)(=O)c2ccc(N)cc2)nc(OC)n1.[Na+]\nSULFADIMETHOXINE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(/C=C\\c2cc(OC)c(OC)c(OC)c2)c(O)c1O\nCandidate Name: COMBRETASTATIN A-1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(/C=C\\c2cc(OC)c(OC)c(OC)c2)c(O)c1O\nCandidate Name: COMBRETASTATIN A-1", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C\nDISOGLUSIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 576.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C\nDISOGLUSIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 576.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC.Cl.O\nName: METOCLOPRAMIDE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC.Cl.O\nName: METOCLOPRAMIDE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O\nEPINEPHRINE BITARTRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O\nEPINEPHRINE BITARTRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nClc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1\nName: CLOPERASTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nClc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1\nName: CLOPERASTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)CCCCCCCC(=O)O\nAZELAIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 188.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)CCCCCCCC(=O)O\nAZELAIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 188.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21\nDrug Name: ERGOTAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 581.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21\nDrug Name: ERGOTAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 581.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nC=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: METHOHEXITAL SODIUM\n\n### Structure\n```\nC=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 284.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.31 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nC=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]", "output": "## Molecular Property Analysis: METHOHEXITAL SODIUM\n\n### Structure\n```\nC=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 284.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.31 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCCCCCCCCCCCSCC(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.51 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCCCCCCCCCCCSCC(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.51 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1OCCC1C1(O)CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1\nDrug Name: FUROMAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 459.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1OCCC1C1(O)CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1\nDrug Name: FUROMAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 459.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=P(O)(O)O.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 363.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=P(O)(O)O.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 363.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 458.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.01 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 458.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.01 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O\nGLUCURONAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 133.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O\nGLUCURONAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 133.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNCc1ccccc1Sc1ccccc1CO\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 245.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNCc1ccccc1Sc1ccccc1CO", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 245.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12\nUPADACITINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 380.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12\nUPADACITINIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 380.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1\nCandidate Name: ONDELOPRAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1\nCandidate Name: ONDELOPRAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O\nDrug Name: BENZTHIAZIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 431.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O\nDrug Name: BENZTHIAZIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 431.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC1(c2ccccc2)C(=O)NC(=O)N(C)C1=O\nCandidate Name: MEPHOBARBITAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC1(c2ccccc2)C(=O)NC(=O)N(C)C1=O\nCandidate Name: MEPHOBARBITAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CNCCSC1=Cc2ccccc2Oc2ccc(F)cc21\nCandidate Name: FLURADOLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CNCCSC1=Cc2ccccc2Oc2ccc(F)cc21\nCandidate Name: FLURADOLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1c(F)cccc1CCCCOc1ccc(C#Cc2ccc(F)c3c(CCCC(=O)O)c(C)n(CCCC(=O)O)c23)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 601.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.61 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1c(F)cccc1CCCCOc1ccc(C#Cc2ccc(F)c3c(CCCC(=O)O)c(C)n(CCCC(=O)O)c23)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 601.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.61 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)[C@@H]1CC[C@@H](C)C[C@H]1O\nLEVOMENTHOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 156.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)[C@@H]1CC[C@@H](C)C[C@H]1O\nLEVOMENTHOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 156.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)Nc1c(Br)cc(Br)cc1CN(C)C12CC3CC(CC(C3)C1)C2\nDrug Name: ADAMEXINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)Nc1c(Br)cc(Br)cc1CN(C)C12CC3CC(CC(C3)C1)C2\nDrug Name: ADAMEXINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nBr.Nc1nc(=O)c2c([nH]1)N[C@@H]1O[C@@H]3COP(=O)(O)O[C@@H]3C(O)(O)[C@@H]1N2.O.O\nName: FOSDENOPTERIN HYDROBROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nBr.Nc1nc(=O)c2c([nH]1)N[C@@H]1O[C@@H]3COP(=O)(O)O[C@@H]3C(O)(O)[C@@H]1N2.O.O\nName: FOSDENOPTERIN HYDROBROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)CCOCCOC(=O)C1(c2ccccc2)CCCC1\nDrug Name: MINEPENTATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)CCOCCOC(=O)C1(c2ccccc2)CCCC1\nDrug Name: MINEPENTATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO\nCandidate Name: BELINOSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO\nCandidate Name: BELINOSTAT", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O\nDrug Name: HETACILLIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 389.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O\nDrug Name: HETACILLIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 389.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cccc(C(=O)CCN[C@@H](C)[C@H](O)c2ccccc2)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cccc(C(=O)CCN[C@@H](C)[C@H](O)c2ccccc2)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccc(CNCC(O)COc2ccc3[nH]c(=O)ccc3c2)cc1OC\nTOBORINONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccc(CNCC(O)COc2ccc3[nH]c(=O)ccc3c2)cc1OC\nTOBORINONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Oc2c(C)c(C)c3c(c2C)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O3)C(C)(C)CCC1\nDrug Name: TRETINOIN TOCOFERIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 713.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 14.57 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Oc2c(C)c(C)c3c(c2C)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O3)C(C)(C)CCC1\nDrug Name: TRETINOIN TOCOFERIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 713.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 14.57 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCCCCCCCCCCCC[N+](C)(C)C1CCCCC1O\nCETHEXONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 368.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCCCCCCCCCCCC[N+](C)(C)C1CCCCC1O\nCETHEXONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 368.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: OLANZAPINE\n\n### Structure\n```\nCc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 312.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.44 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 30.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.810\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1", "output": "## Molecular Property Analysis: OLANZAPINE\n\n### Structure\n```\nCc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 312.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.44 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 30.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.810\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)NCC(O)COc1cccc2[nH]ccc12\nPINDOLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)NCC(O)COc1cccc2[nH]ccc12\nPINDOLOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl\nDrug Name: DULOXETINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl\nDrug Name: DULOXETINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)[N-]S(=O)(=O)c1ccc(N)cc1.O.[Na+]\nCandidate Name: SULFACETAMIDE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)[N-]S(=O)(=O)c1ccc(N)cc1.O.[Na+]\nCandidate Name: SULFACETAMIDE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)NC(=O)CN1CCN(Cc2nc3ccccc3n2CCC(=O)c2ccccc2)CC1\nName: NILPRAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 447.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)NC(=O)CN1CCN(Cc2nc3ccccc3n2CCC(=O)c2ccccc2)CC1\nName: NILPRAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 447.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC=C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C\nName: NORVINISTERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 300.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC=C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C\nName: NORVINISTERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 300.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc2c(c1)C(N1CCN(C)CC1)=Nc1ccccc1S2\nCandidate Name: METIAPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 18.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc2c(c1)C(N1CCN(C)CC1)=Nc1ccccc1S2\nCandidate Name: METIAPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 18.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: NS(=O)(=O)c1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1\nCandidate Name: SUCLOFENIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: NS(=O)(=O)c1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1\nCandidate Name: SUCLOFENIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2\nName: PRASUGREL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2\nName: PRASUGREL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nWhich drug candidate has better development potential?\nA: CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O (IRINOTECAN HYDROCHLORIDE)\nB: Cc1c(C(=O)NN2CCCCC2)c(-c2ccc(Cl)cc2)nn1-c1ccc(Cl)cc1 (Rimonabant (Acomplia))\n<|im_end|>\n<|im_start|>assistant\n## Comparative Drug Analysis\n\n### Head-to-Head Comparison\n\n| Property | IRINOTECAN HYDROCHLORIDE | Rimonabant (Acomplia) | Better |\n|----------|---------|---------|--------|\n| Status | approved | withdrawn | üèÜ IRINOTECAN HYDROCHLORIDE |\n| Mol. Weight | nan Da | nan Da | üèÜ Rimonabant (Acomplia) |\n| LogP | nan | nan | üèÜ Rimonabant (Acomplia) |\n| PSA | nan √Ö¬≤ | nan √Ö¬≤ | üèÜ Rimonabant (Acomplia) |\n\n### Assessment\n\n**IRINOTECAN HYDROCHLORIDE** is the clear winner as it has achieved regulatory approval, demonstrating successful clinical development with an acceptable safety/efficacy profile.\n\n**Rimonabant (Acomplia)** has not achieved approval, which may indicate:\n- Efficacy challenges in clinical trials\n- Safety concerns that limited development\n- Strategic decision to discontinue development\n<|im_end|>", "instruction": "Which drug candidate has better development potential?\nA: CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O (IRINOTECAN HYDROCHLORIDE)\nB: Cc1c(C(=O)NN2CCCCC2)c(-c2ccc(Cl)cc2)nn1-c1ccc(Cl)cc1 (Rimonabant (Acomplia))", "output": "## Comparative Drug Analysis\n\n### Head-to-Head Comparison\n\n| Property | IRINOTECAN HYDROCHLORIDE | Rimonabant (Acomplia) | Better |\n|----------|---------|---------|--------|\n| Status | approved | withdrawn | üèÜ IRINOTECAN HYDROCHLORIDE |\n| Mol. Weight | nan Da | nan Da | üèÜ Rimonabant (Acomplia) |\n| LogP | nan | nan | üèÜ Rimonabant (Acomplia) |\n| PSA | nan √Ö¬≤ | nan √Ö¬≤ | üèÜ Rimonabant (Acomplia) |\n\n### Assessment\n\n**IRINOTECAN HYDROCHLORIDE** is the clear winner as it has achieved regulatory approval, demonstrating successful clinical development with an acceptable safety/efficacy profile.\n\n**Rimonabant (Acomplia)** has not achieved approval, which may indicate:\n- Efficacy challenges in clinical trials\n- Safety concerns that limited development\n- Strategic decision to discontinue development", "task_type": "comparison"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)CSC(CCCc1ccccc1)c1ccc(OCc2ccc3ccccc3n2)cc1\nName: AZD-4769\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.70 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)CSC(CCCc1ccccc1)c1ccc(OCc2ccc3ccccc3n2)cc1\nName: AZD-4769", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.70 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)CC(C)(C)c1ccc(OCCOCCOCCOCCOCCOCCOCCO)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 514.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)CC(C)(C)c1ccc(OCCOCCOCCOCCOCCOCCOCCO)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 514.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCN(c2cc3c(nn2)Oc2ccccc2N3C)CC1\nPIPOFEZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCN(c2cc3c(nn2)Oc2ccccc2N3C)CC1\nPIPOFEZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nCandidate Name: PREDNISOLONE ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nCandidate Name: PREDNISOLONE ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O\nIDEBENONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 338.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O\nIDEBENONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 338.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=[Si](O)O[Si](O)(O)O[Si](=O)O\nDrug Name: TRISILICATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 216.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=[Si](O)O[Si](O)(O)O[Si](=O)O\nDrug Name: TRISILICATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 216.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CSc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2\nDrug Name: METITEPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CSc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2\nDrug Name: METITEPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Clc1ccc2nsnc2c1NC1=NCCN1\nDrug Name: TIZANIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Clc1ccc2nsnc2c1NC1=NCCN1\nDrug Name: TIZANIDINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C\nName: CHENODIOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 392.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C\nName: CHENODIOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 392.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@]2(C(=O)CCl)O1\nCandidate Name: TRICLONIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 505.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@]2(C(=O)CCl)O1\nCandidate Name: TRICLONIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 505.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)SC[C@@H](Cc1ccc2c(c1)OCO2)C(=O)N[C@@H](C)C(=O)OCc1ccccc1\nFASIDOTRIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)SC[C@@H](Cc1ccc2c(c1)OCO2)C(=O)N[C@@H](C)C(=O)OCc1ccccc1\nFASIDOTRIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1\nGSK-1292263\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 456.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1\nGSK-1292263", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 456.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=[N+]([O-])OCC(CCl)O[N+](=O)[O-]\nCandidate Name: CLONITRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=[N+]([O-])OCC(CCl)O[N+](=O)[O-]\nCandidate Name: CLONITRATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@@H](N/C(=N\\C#N)Nc1ccc(C#N)cc1)C(C)(C)C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 269.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@@H](N/C(=N\\C#N)Nc1ccc(C#N)cc1)C(C)(C)C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 269.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl\nDrug Name: RESATORVID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl\nDrug Name: RESATORVID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12\nMETHYLPREDNISOLONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 374.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12\nMETHYLPREDNISOLONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 374.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1.CS(=O)(=O)O\nDrug Name: NAQUOTINIB MESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 658.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 120.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1.CS(=O)(=O)O\nDrug Name: NAQUOTINIB MESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 658.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 120.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)C(=O)[O-].[Na+]\nName: PYRUVATE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 110.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)C(=O)[O-].[Na+]\nName: PYRUVATE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 110.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)[O-].O.[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 510.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)[O-].O.[Na+]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 510.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)(Cc1ccc(Oc2ncccc2C#N)cc1)NC[C@H](O)COc1ccccc1-c1cccs1\nCandidate Name: LUBABEGRON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 499.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.82 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)(Cc1ccc(Oc2ncccc2C#N)cc1)NC[C@H](O)COc1ccccc1-c1cccs1\nCandidate Name: LUBABEGRON", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 499.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.82 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC\nMITEMCINAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 756.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 151.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC\nMITEMCINAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 756.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 151.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)NCCCN1CCN(c2cc(Cl)ccc2Cl)CC1\nACAPRAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 330.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)NCCCN1CCN(c2cc(Cl)ccc2Cl)CC1\nACAPRAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 330.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNC1=NCC(c2ccccc2)O1\nName: AMINOREX\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 162.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNC1=NCC(c2ccccc2)O1\nName: AMINOREX", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 162.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(Oc1cccc2ccccc12)/C(N)=N/O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 230.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(Oc1cccc2ccccc12)/C(N)=N/O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 230.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1\nDOFETILIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1\nDOFETILIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCOCC(O)COCCCC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 204.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCOCC(O)COCCCC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 204.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1\nDrug Name: NICARDIPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 479.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 111.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1\nDrug Name: NICARDIPINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 479.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 111.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOCCCN1CCN(c2ccccc2OC)CC1\nDIMETHOLIZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOCCCN1CCN(c2ccccc2OC)CC1\nDIMETHOLIZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)/N=c1\\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1\nCandidate Name: CLOFAZIMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 473.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.49 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)/N=c1\\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1\nCandidate Name: CLOFAZIMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 473.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.49 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\\C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 432.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\\C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 432.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)OC1(C(C)CN(C)C)CCCCC1c1ccccc1\nDrug Name: NEXERIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)OC1(C(C)CN(C)C)CCCCC1c1ccccc1\nDrug Name: NEXERIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C\nDrug Name: DESOXYCORTICOSTERONE PIVALATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 414.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.29 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C\nDrug Name: DESOXYCORTICOSTERONE PIVALATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 414.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.29 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O\nCandidate Name: ADENOSINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 139.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O\nCandidate Name: ADENOSINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 139.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\\C)CCC=C(C)C\nCandidate Name: LYCOPENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 536.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 12.94 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\\C)CCC=C(C)C\nCandidate Name: LYCOPENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 536.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 12.94 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN1CC[C@@]2(C)c3cc(OC(=O)N4CCc5ccccc5C4)ccc3N(C)[C@@H]12\nDrug Name: QUILOSTIGMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN1CC[C@@]2(C)c3cc(OC(=O)N4CCc5ccccc5C4)ccc3N(C)[C@@H]12\nDrug Name: QUILOSTIGMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1C(=O)CN2CCc3ccccc3C2c2cc(Cl)ccc21\nCLAZOLAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 312.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1C(=O)CN2CCc3ccccc3C2c2cc(Cl)ccc21\nCLAZOLAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 312.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 395.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 395.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNc1ccc(S(=O)(=O)Nc2cnc3c(Cl)cccc3n2)cc1\nName: CHLORSULFAQUINOXALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNc1ccc(S(=O)(=O)Nc2cnc3c(Cl)cccc3n2)cc1\nName: CHLORSULFAQUINOXALINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCOc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TERAZOSIN\n\n### Structure\n```\nCOc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 387.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.06 | 0-5 | ‚úì |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 103.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.830\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCOc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC", "output": "## Molecular Property Analysis: TERAZOSIN\n\n### Structure\n```\nCOc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 387.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.06 | 0-5 | ‚úì |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 103.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.830\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCNCC(O)c1cccc(O)c1\nCandidate Name: ETILEFRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 181.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCNCC(O)c1cccc(O)c1\nCandidate Name: ETILEFRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 181.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: NC(=O)c1ccc([N+](=O)[O-])cc1Cl\nCandidate Name: AKLOMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: NC(=O)c1ccc([N+](=O)[O-])cc1Cl\nCandidate Name: AKLOMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CNC(=O)Oc1ccccc1C(=O)Nc1ccccc1\nDrug Name: ANILAMATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CNC(=O)Oc1ccccc1C(=O)Nc1ccccc1\nDrug Name: ANILAMATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCOCCOCCOCCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I\nDrug Name: IOTRANIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1243.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCOCCOCCOCCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I\nDrug Name: IOTRANIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1243.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1ccc(C(C)C)cc1O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CARVACROL\n\n### Structure\n```\nCc1ccc(C(C)C)cc1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 150.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.82 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 20.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.650\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1ccc(C(C)C)cc1O", "output": "## Molecular Property Analysis: CARVACROL\n\n### Structure\n```\nCc1ccc(C(C)C)cc1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 150.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.82 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 20.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.650\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOC(Nc1ccc(C(=O)O)cc1)C(=O)c1ccc(-c2ccccc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOC(Nc1ccc(C(=O)O)cc1)C(=O)c1ccc(-c2ccccc2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C1c2ccccc2C(=O)c2c1cn1c2Cc2ccccc2C1\nMITOQUIDONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C1c2ccccc2C(=O)c2c1cn1c2Cc2ccccc2C1\nMITOQUIDONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC\nLOMERIZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 468.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC\nLOMERIZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 468.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl\nCandidate Name: PRASUGREL HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 409.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl\nCandidate Name: PRASUGREL HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 409.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nThis drug failed in Phase II/III. Explain why:\nDrug: Atabecestat\nSMILES: CC(C)(C)NC(=O)C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2\n<|im_end|>\n<|im_start|>assistant\n## Drug Failure Analysis: Atabecestat\n\n### Summary\n**Phase Failed:** Phase II/III\n**Year:** 2018.0\n**Therapeutic Area:** CNS/Neurology\n**Failure Category:** Safety/Efficacy\n\n### Detailed Failure Reason\n\nLiver enzyme elevations and worsening cognition\n\n### Mechanism of Toxicity\n\nnan\n\n### Efficacy Failure Analysis\n\n**Common Reasons for Efficacy Failure:**\n1. **Target Selection Issues:** Pre-clinical models may not accurately reflect human disease biology\n2. **Patient Population Heterogeneity:** Subgroups may respond differently\n3. **Dose Selection:** May not achieve adequate target engagement\n4. **Biomarker Disconnect:** Surrogate endpoints may not correlate with clinical outcomes\n\n**Prevention Strategies:**\n- Extensive target validation using human genetics data\n- Biomarker-driven patient stratification\n- PK/PD modeling to optimize dosing\n- Adaptive trial designs\n\n### Key Takeaways for Drug Development\n\n1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development\n2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks\n3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring\n4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy\n<|im_end|>", "instruction": "This drug failed in Phase II/III. Explain why:\nDrug: Atabecestat\nSMILES: CC(C)(C)NC(=O)C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2", "output": "## Drug Failure Analysis: Atabecestat\n\n### Summary\n**Phase Failed:** Phase II/III\n**Year:** 2018.0\n**Therapeutic Area:** CNS/Neurology\n**Failure Category:** Safety/Efficacy\n\n### Detailed Failure Reason\n\nLiver enzyme elevations and worsening cognition\n\n### Mechanism of Toxicity\n\nnan\n\n### Efficacy Failure Analysis\n\n**Common Reasons for Efficacy Failure:**\n1. **Target Selection Issues:** Pre-clinical models may not accurately reflect human disease biology\n2. **Patient Population Heterogeneity:** Subgroups may respond differently\n3. **Dose Selection:** May not achieve adequate target engagement\n4. **Biomarker Disconnect:** Surrogate endpoints may not correlate with clinical outcomes\n\n**Prevention Strategies:**\n- Extensive target validation using human genetics data\n- Biomarker-driven patient stratification\n- PK/PD modeling to optimize dosing\n- Adaptive trial designs\n\n### Key Takeaways for Drug Development\n\n1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development\n2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks\n3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring\n4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy", "task_type": "failure_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O\nCandidate Name: AMODIAQUINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O\nCandidate Name: AMODIAQUINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCOc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: NAFOXIDINE\n\n### Structure\n```\nCOc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 425.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 6.08 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 21.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.460\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCOc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1", "output": "## Molecular Property Analysis: NAFOXIDINE\n\n### Structure\n```\nCOc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 425.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 6.08 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 21.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.460\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O\nCandidate Name: CPG-52852\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 102.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O\nCandidate Name: CPG-52852", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 102.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCCC/C=C\\CCCCCCCC(=O)NCc1ccc(O)c(OC)c1\nName: OLVANIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 417.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.05 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCCC/C=C\\CCCCCCCC(=O)NCc1ccc(O)c(OC)c1\nName: OLVANIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 417.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.05 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC/C(=C(\\CCOC(=O)c1ccccc1)SS/C(CCOC(=O)c1ccccc1)=C(/C)N(C=O)Cc1cnc(C)nc1N)N(C=O)Cc1cnc(C)nc1N\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 770.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 196.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC/C(=C(\\CCOC(=O)c1ccccc1)SS/C(CCOC(=O)c1ccccc1)=C(/C)N(C=O)Cc1cnc(C)nc1N)N(C=O)Cc1cnc(C)nc1N", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 770.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 196.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCN1CC(c2ccc(S(C)(=O)=O)cc2)=C(c2ccc(C)cc2)C1=O\nDrug Name: IMRECOXIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCN1CC(c2ccc(S(C)(=O)=O)cc2)=C(c2ccc(C)cc2)C1=O\nDrug Name: IMRECOXIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 319.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 319.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC1CCc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23\nDrug Name: VEBUFLOXACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 359.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC1CCc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23\nDrug Name: VEBUFLOXACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 359.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O\nIDARUBICIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 497.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 176.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O\nIDARUBICIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 497.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 176.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O\nEPHEDRINE SULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 428.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O\nEPHEDRINE SULFATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 428.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CNC[C@H](O)CC12CCC(c3ccccc31)c1ccccc12\nDrug Name: LEVOPROTILINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 293.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CNC[C@H](O)CC12CCC(c3ccccc31)c1ccccc12\nDrug Name: LEVOPROTILINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 293.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1\nGSK189254\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 351.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1\nGSK189254", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 351.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21\nCandidate Name: PHENOLPHTHALEIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21\nCandidate Name: PHENOLPHTHALEIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C\nName: ANECORTAVE ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 386.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C\nName: ANECORTAVE ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 386.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 133.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 133.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCN2c3ncccc3Cc3ccccc3C2C1\nMIRTAZAPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCN2c3ncccc3Cc3ccccc3C2C1\nMIRTAZAPINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCn1cc(C[C@@H](N)C(=O)O)c2ccccc21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 218.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCn1cc(C[C@@H](N)C(=O)O)c2ccccc21", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 218.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nName: PREDNISOLONE TEBUTATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 458.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nName: PREDNISOLONE TEBUTATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 458.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1[nH]c(/C=C2\\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1\nDrug Name: SU-014813\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 442.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1[nH]c(/C=C2\\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1\nDrug Name: SU-014813", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 442.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1c(NC/C=C\\COc2cc(CN3CCCCC3)ccn2)c(=O)c1=O\nPIBUTIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1c(NC/C=C\\COc2cc(CN3CCCCC3)ccn2)c(=O)c1=O\nPIBUTIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc(OCCC[N+](C)(C)Cc2ccc(Br)cc2)c(C(C)C)cc1Cl\nCandidate Name: HALOPENIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.58 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc(OCCC[N+](C)(C)Cc2ccc(Br)cc2)c(C(C)C)cc1Cl\nCandidate Name: HALOPENIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.58 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1.O=C(O)CCC(=O)O\nDrug Name: PRUCALOPRIDE SUCCINATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 486.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1.O=C(O)CCC(=O)O\nDrug Name: PRUCALOPRIDE SUCCINATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 486.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc([C@@H]2CC[C@@H](c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C\nCandidate Name: OMBITASVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 894.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.69 | ‚ö† High (>5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 178.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc([C@@H]2CC[C@@H](c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C\nCandidate Name: OMBITASVIR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 894.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.69 | ‚ö† High (>5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 178.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN[C@@H]1CCN(c2cc(NCC3CC3)nc(N)n2)C1\nDrug Name: ADRIFORANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 262.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN[C@@H]1CCN(c2cc(NCC3CC3)nc(N)n2)C1\nDrug Name: ADRIFORANT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 262.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCOC(=O)c1ccc(N)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: BENZOCAINE\n\n### Structure\n```\nCCOC(=O)c1ccc(N)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 165.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.45 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 52.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.530\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCOC(=O)c1ccc(N)cc1", "output": "## Molecular Property Analysis: BENZOCAINE\n\n### Structure\n```\nCCOC(=O)c1ccc(N)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 165.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.45 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 52.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.530\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: OC(COc1cccc2[nH]ccc12)CN1CCC(COc2ccccc2)CC1\nCandidate Name: MINDODILOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 380.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: OC(COc1cccc2[nH]ccc12)CN1CCC(COc2ccccc2)CC1\nCandidate Name: MINDODILOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 380.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1\nEDATREXATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 467.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 207.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1\nEDATREXATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 467.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 207.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc(O)c2c(c1)C(=O)c1cc3c(c(O)c1C2=O)[C@@H](O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1OC)[C@H](OC)[C@](C)(O)C3=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 574.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 198.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc(O)c2c(c1)C(=O)c1cc3c(c(O)c1C2=O)[C@@H](O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1OC)[C@H](OC)[C@](C)(O)C3=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 574.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 198.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: FLUMAZENIL\n\n### Structure\n```\nCCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 303.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.77 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 64.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.790\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2", "output": "## Molecular Property Analysis: FLUMAZENIL\n\n### Structure\n```\nCCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 303.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.77 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 64.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.790\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)NCC(O)COc1cccc2c1C(=O)OC2\nDrug Name: AFUROLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 279.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)NCC(O)COc1cccc2c1C(=O)OC2\nDrug Name: AFUROLOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 279.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C\nNIRMATRELVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C\nNIRMATRELVIR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 268.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 268.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)OC(=O)CCC/C=C\\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 432.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)OC(=O)CCC/C=C\\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 432.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cnns3)CS[C@H]12)c1csc(N)n1\nDrug Name: CEFUZONAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 513.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 173.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cnns3)CS[C@H]12)c1csc(N)n1\nDrug Name: CEFUZONAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 513.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 173.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TOLBUTAMIDE\n\n### Structure\n```\nCCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 270.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.78 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 75.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1", "output": "## Molecular Property Analysis: TOLBUTAMIDE\n\n### Structure\n```\nCCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 270.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.78 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 75.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCOc1cc2c(cc1OC)-c1c/c(=N\\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TREQUINSIN\n\n### Structure\n```\nCOc1cc2c(cc1OC)-c1c/c(=N\\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 405.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.58 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 57.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCOc1cc2c(cc1OC)-c1c/c(=N\\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2", "output": "## Molecular Property Analysis: TREQUINSIN\n\n### Structure\n```\nCOc1cc2c(cc1OC)-c1c/c(=N\\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 405.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.58 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 57.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O.Cl\nCandidate Name: YOHIMBINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O.Cl\nCandidate Name: YOHIMBINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN[C@@H](C)[C@H](O)c1ccccc1\nDrug Name: EPHEDRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 165.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN[C@@H](C)[C@H](O)c1ccccc1\nDrug Name: EPHEDRINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 165.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: OXOLINIC ACID\n\n### Structure\n```\nCCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 261.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.45 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.880\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3", "output": "## Molecular Property Analysis: OXOLINIC ACID\n\n### Structure\n```\nCCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 261.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.45 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.880\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C1Nc2ccccc2C(c2ccccc2)N1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1\nCandidate Name: AFACIFENACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 481.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.19 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C1Nc2ccccc2C(c2ccccc2)N1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1\nCandidate Name: AFACIFENACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 481.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.19 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MARALIXIBAT CHLORIDE\n\n### Structure\n```\nCCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 710.4 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 6.62 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 70.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 13.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.210\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]", "output": "## Molecular Property Analysis: MARALIXIBAT CHLORIDE\n\n### Structure\n```\nCCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 710.4 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 6.62 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 70.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 13.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.210\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCCCC(CCC)C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: VALPROIC ACID\n\n### Structure\n```\nCCCC(CCC)C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 144.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 2.29 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.640\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCCCC(CCC)C(=O)O", "output": "## Molecular Property Analysis: VALPROIC ACID\n\n### Structure\n```\nCCCC(CCC)C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 144.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 2.29 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.640\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc2oc(=O)c(C)c(C)c2cc1OCCCN1CCN(c2ccccc2OC)CC1\nENSACULIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc2oc(=O)c(C)c(C)c2cc1OCCCN1CCN(c2ccccc2OC)CC1\nENSACULIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCl.NCCc1ccc(O)c(O)c1\nDOPAMINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 189.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCl.NCCc1ccc(O)c(O)c1\nDOPAMINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 189.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ncc(F)cn4)nc32)n[nH]1\nAZD-7451\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ncc(F)cn4)nc32)n[nH]1\nAZD-7451", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(SC(=S)Nc1ccc(NC(=S)SC(C)c2nc3ccccc3n2C)cc1)c1nc2ccccc2n1C\nDrug Name: BISBENDAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 576.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.84 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(SC(=S)Nc1ccc(NC(=S)SC(C)c2nc3ccccc3n2C)cc1)c1nc2ccccc2n1C\nDrug Name: BISBENDAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 576.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.84 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC\nDrug Name: ALIZAPRIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC\nDrug Name: ALIZAPRIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O\nName: BENZQUINAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O\nName: BENZQUINAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O=[N+]([O-])[O-]\nCandidate Name: METHYLATROPINE NITRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O=[N+]([O-])[O-]\nCandidate Name: METHYLATROPINE NITRATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc(-c2ccc(=O)[nH]n2)ccc1OC(F)F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 268.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc(-c2ccc(=O)[nH]n2)ccc1OC(F)F", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 268.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nc1ccc(CCN2CCC(CCc3c[nH]c4ccccc34)CC2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.06 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nc1ccc(CCN2CCC(CCc3c[nH]c4ccccc34)CC2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.06 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\n[O-][N+]1=C(c2ccccc2)c2cc(Cl)ccc2N=C(NCC2CC2)C1\nName: CYPRAZEPAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 339.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\n[O-][N+]1=C(c2ccccc2)c2cc(Cl)ccc2N=C(NCC2CC2)C1\nName: CYPRAZEPAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 339.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)O[C@H](C)OC(=O)OCC)O1\nDrug Name: ITROCINONIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 568.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)O[C@H](C)OC(=O)OCC)O1\nDrug Name: ITROCINONIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 568.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1\nDrug Name: RUBOXISTAURIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 468.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1\nDrug Name: RUBOXISTAURIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 468.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccccc1N1CCN(CC(O)COc2ccc(-c3cc(C#N)c(=O)[nH]c3C)cc2)CC1\nSATERINONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 474.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccccc1N1CCN(CC(O)COc2ccc(-c3cc(C#N)c(=O)[nH]c3C)cc2)CC1\nSATERINONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 474.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cl.N=C(N)NC(=O)c1nc(Cl)c(N)nc1N.O.O\nDrug Name: AMILORIDE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 156.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cl.N=C(N)NC(=O)c1nc(Cl)c(N)nc1N.O.O\nDrug Name: AMILORIDE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 156.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc([S+](C)[O-])ccc1-c1nc2cnccc2[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 287.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc([S+](C)[O-])ccc1-c1nc2cnccc2[nH]1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 287.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: N#Cc1ccc2c(c1)C1=C(CCN(CC3CCCC3)CC1)c1ccccc1O2\nDrug Name: SAVOXEPIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: N#Cc1ccc2c(c1)C1=C(CCN(CC3CCCC3)CC1)c1ccccc1O2\nDrug Name: SAVOXEPIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N\nCandidate Name: ZANAMIVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 198.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N\nCandidate Name: ZANAMIVIR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 198.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)CCCC/C=C(/c1ccccc1)c1cccnc1\nDrug Name: ISBOGREL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)CCCC/C=C(/c1ccccc1)c1cccnc1\nDrug Name: ISBOGREL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCn1c(=O)c2c(ncn2CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)n(C)c1=O\nFLUPROFYLLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 427.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCn1c(=O)c2c(ncn2CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)n(C)c1=O\nFLUPROFYLLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 427.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 483.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 483.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1c(CCN2CCOCC2)c(=O)oc2cc(NC(=O)N3CCOCC3)ccc12\nName: MOROCROMEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1c(CCN2CCOCC2)c(=O)oc2cc(NC(=O)N3CCOCC3)ccc12\nName: MOROCROMEN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[N+]1(CCC(C(N)=O)(c2ccccc2)c2ccccc2)CCCCC1.[Br-]\nCandidate Name: FENPIVERINIUM BROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 417.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[N+]1(CCC(C(N)=O)(c2ccccc2)c2ccccc2)CCCCC1.[Br-]\nCandidate Name: FENPIVERINIUM BROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 417.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCc1ccc2c(c1)N(CC(C)CN(C)C)c1ccccc1S2\nDrug Name: ETYMEMAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.05 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCc1ccc2c(c1)N(CC(C)CN(C)C)c1ccccc1S2\nDrug Name: ETYMEMAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.05 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccc(O)c2ncccc12\nDrug Name: TILIQUINOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 159.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccc(O)c2ncccc12\nDrug Name: TILIQUINOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 159.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nN[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1.O\nName: CEFACLOR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 385.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nN[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1.O\nName: CEFACLOR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 385.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccccc1N1CCN(CCCOc2ccccn2)CC1\nCandidate Name: TOPRILIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccccc1N1CCN(CCCOc2ccccn2)CC1\nCandidate Name: TOPRILIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nN[C@H](CF)C(=O)O\nFLUDALANINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 107.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nN[C@H](CF)C(=O)O\nFLUDALANINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 107.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccccc1OCCNCC(O)COc1cccc2[nH]nnc12\nCandidate Name: TRIBENDILOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccccc1OCCNCC(O)COc1cccc2[nH]nnc12\nCandidate Name: TRIBENDILOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1\nDrug Name: FENOLDOPAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1\nDrug Name: FENOLDOPAM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(O[C@H]1CN[C@H](C(=O)O)C1)c1cccs1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 241.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(O[C@H]1CN[C@H](C(=O)O)C1)c1cccs1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 241.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN[C@@H]1CC[C@@H](c2ccccc2)c2ccccc21\nDrug Name: TAMETRALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 237.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN[C@@H]1CC[C@@H](c2ccccc2)c2ccccc21\nDrug Name: TAMETRALINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 237.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1cc(C)cc(OCC2CNC(=O)O2)c1\nMETAXALONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 221.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1cc(C)cc(OCC2CNC(=O)O2)c1\nMETAXALONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 221.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: GREPAFLOXACIN\n\n### Structure\n```\nCc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 359.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.28 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 74.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.880\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1", "output": "## Molecular Property Analysis: GREPAFLOXACIN\n\n### Structure\n```\nCc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 359.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.28 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 74.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.880\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(C(=O)Nc2nc(=O)n([C@@H]3O[C@H](C)[C@@H](O)[C@H]3O)cc2F)cc(OC)c1OC\nName: GALOCITABINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 141.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(C(=O)Nc2nc(=O)n([C@@H]3O[C@H](C)[C@@H](O)[C@H]3O)cc2F)cc(OC)c1OC\nName: GALOCITABINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 141.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: [Na+].[O-]Cl\nCandidate Name: SODIUM HYPOCHLORITE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 74.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: [Na+].[O-]Cl\nCandidate Name: SODIUM HYPOCHLORITE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 74.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C\nSELURAMPANEL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C\nSELURAMPANEL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCSc1ncc(OCC#CI)cn1\nRIMOPROGIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCSc1ncc(OCC#CI)cn1\nRIMOPROGIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nOc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: HIGENAMINE\n\n### Structure\n```\nOc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 271.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.23 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.630\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nOc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1", "output": "## Molecular Property Analysis: HIGENAMINE\n\n### Structure\n```\nOc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 271.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.23 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.630\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1=Nc2ccc(Cl)cc2S(=O)(=O)N1\nName: DIAZOXIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 230.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1=Nc2ccc(Cl)cc2S(=O)(=O)N1\nName: DIAZOXIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 230.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCSc1ccccc1N1CCN(CCCCn2c(=O)[nH]c3ccccc3c2=O)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCSc1ccccc1N1CCN(CCCCn2c(=O)[nH]c3ccccc3c2=O)CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1ccncc1N\nAMIFAMPRIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 109.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1ccncc1N\nAMIFAMPRIDINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 109.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nc1ccc(C(Cc2noc(CCN3CCCCC3)n2)c2ccccc2)cc1\nPRENOXDIAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nc1ccc(C(Cc2noc(CCN3CCCCC3)n2)c2ccccc2)cc1\nPRENOXDIAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)cc1I\nName: FIALURIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)cc1I\nName: FIALURIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1\nCandidate Name: FISPEMIFENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 422.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.66 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1\nCandidate Name: FISPEMIFENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 422.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.66 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=c1nc2cccccc-2n1Cc1ccccc1\nName: BENHEPAZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=c1nc2cccccc-2n1Cc1ccccc1\nName: BENHEPAZONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1nc2c(ncn2/C=C2/CC2(CO)CO)c(=O)[nH]1\nFILOCICLOVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 263.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1nc2c(ncn2/C=C2/CC2(CO)CO)c(=O)[nH]1\nFILOCICLOVIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 263.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1\nDrug Name: BAVISANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1\nDrug Name: BAVISANT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)NCC(O)COc1cccc2ccccc12\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PROPRANOLOL\n\n### Structure\n```\nCC(C)NCC(O)COc1cccc2ccccc12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 259.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.58 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 41.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.840\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)NCC(O)COc1cccc2ccccc12", "output": "## Molecular Property Analysis: PROPRANOLOL\n\n### Structure\n```\nCC(C)NCC(O)COc1cccc2ccccc12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 259.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.58 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 41.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.840\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)n1ccn(C)c1=S\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 186.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)n1ccn(C)c1=S", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 186.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNc1nc(C(=O)N[C@H](CO)C(=O)O)c(N)nc1C(=O)N[C@H](CO)C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 251.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNc1nc(C(=O)N[C@H](CO)C(=O)O)c(N)nc1C(=O)N[C@H](CO)C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 251.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nAMEBUCORT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 488.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nAMEBUCORT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 488.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1\nName: LANDIOLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 509.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 127.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1\nName: LANDIOLOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 509.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 127.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(O)c(-n2nc3ccccc3n2)c1\nCandidate Name: DROMETRIZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 225.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(O)c(-n2nc3ccccc3n2)c1\nCandidate Name: DROMETRIZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 225.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1\nDrug Name: AVN-944\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 477.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.47 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 138.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1\nDrug Name: AVN-944", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 477.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.47 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 138.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1\nDrug Name: PHA-543613\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1\nDrug Name: PHA-543613", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl\nName: NEFLAMAPIMOD\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 436.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.49 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl\nName: NEFLAMAPIMOD", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 436.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.49 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)Oc1ccccc1C(=O)O.NCCCCC(N)C(=O)O\nASPIRIN DL-LYSINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)Oc1ccccc1C(=O)O.NCCCCC(N)C(=O)O\nASPIRIN DL-LYSINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCC(C#N)(CCCN(C)CCc1ccccc1)c1ccccc1\nCandidate Name: RONIPAMIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 460.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.71 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCC(C#N)(CCCN(C)CCc1ccccc1)c1ccccc1\nCandidate Name: RONIPAMIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 460.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.71 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@@H](Cc1ccccc1)N(C)C\nDrug Name: DIMETAMFETAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 163.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@@H](Cc1ccccc1)N(C)C\nDrug Name: DIMETAMFETAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 163.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)c1ccccc1O\nName: SALICYLIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 138.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)c1ccccc1O\nName: SALICYLIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 138.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21.[Cl-].[Cl-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 527.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.17 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21.[Cl-].[Cl-]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 527.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.17 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C=C1CC[C@H](O)C/C1=C/C=C1\\CCC[C@]2(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(C)O)CC[C@@H]12\nCandidate Name: SECALCIFEROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C=C1CC[C@H](O)C/C1=C/C=C1\\CCC[C@]2(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(C)O)CC[C@@H]12\nCandidate Name: SECALCIFEROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Na+]\nCandidate Name: OMEPRAZOLE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 367.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Na+]\nCandidate Name: OMEPRAZOLE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 367.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\n[Cl-].[Rb+]\nRUBIDIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 120.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\n[Cl-].[Rb+]\nRUBIDIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 120.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCC(CCC)(CCC)C(N)=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 185.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCC(CCC)(CCC)C(N)=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 185.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC(CCCCC1CCC2CC(=O)CC12)OC\nCandidate Name: CIOTERONEL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC(CCCCC1CCC2CC(=O)CC12)OC\nCandidate Name: CIOTERONEL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO\nDrug Name: FRUCTOSE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO\nDrug Name: FRUCTOSE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)[C@H](O)[C@@H](O)C(=O)O\nDrug Name: TARTARIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 150.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)[C@H](O)[C@@H](O)C(=O)O\nDrug Name: TARTARIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 150.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)N[C@@H]1[C@@H](COC[C@@H]2O[C@H](C(=O)O)[C@@H](CO)[C@H](O)[C@H]2O)[C@@H](CS(=O)(=O)O)[C@@H](CO)O[C@H]1CO\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 531.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -4.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 249.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)N[C@@H]1[C@@H](COC[C@@H]2O[C@H](C(=O)O)[C@@H](CO)[C@H](O)[C@H]2O)[C@@H](CS(=O)(=O)O)[C@@H](CO)O[C@H]1CO", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 531.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -4.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 249.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1\nCandidate Name: CETABEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.28 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1\nCandidate Name: CETABEN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.28 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=[N+]([O-])OC[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]\nDrug Name: ERYTHRITYL TETRANITRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 209.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=[N+]([O-])OC[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]\nDrug Name: ERYTHRITYL TETRANITRATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 209.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: [15OH2]\nCandidate Name: WATER O 15\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 17.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 31.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: [15OH2]\nCandidate Name: WATER O 15", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 17.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 31.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@]12CCC(OC3CCCC3)=CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O\nCandidate Name: PENMESTEROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.15 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@]12CCC(OC3CCCC3)=CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O\nCandidate Name: PENMESTEROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.15 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCNC(=S)NCO\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 120.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCNC(=S)NCO", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 120.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN1[C@@H]2CC[C@H]1C[C@@H](OC1c3ccccc3C=Cc3ccccc31)C2\nName: DECITROPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN1[C@@H]2CC[C@H]1C[C@@H](OC1c3ccccc3C=Cc3ccccc31)C2\nName: DECITROPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)COC(=O)CCCc1ccc(N(CCCl)CCCl)cc1\nDrug Name: ATRIMUSTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 720.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)COC(=O)CCCc1ccc(N(CCCl)CCCl)cc1\nDrug Name: ATRIMUSTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 720.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)CN1CCCC1=O\nDrug Name: PIRACETAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 142.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)CN1CCCC1=O\nDrug Name: PIRACETAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 142.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)OC(=O)[C@H](C)N[P@+]([O-])(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@](C)(O)[C@@H]1OC(=O)C(C)C)Oc1ccccc1\nDrug Name: GS-6620\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 644.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 215.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)OC(=O)[C@H](C)N[P@+]([O-])(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@](C)(O)[C@@H]1OC(=O)C(C)C)Oc1ccccc1\nDrug Name: GS-6620", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 644.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 215.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC1(CC)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1\nCandidate Name: AMCINAFAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 462.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC1(CC)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1\nCandidate Name: AMCINAFAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 462.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc2cc([C@H](C)C(=O)O)ccc2c1\nCandidate Name: NAPROXEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 230.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc2cc([C@H](C)C(=O)O)ccc2c1\nCandidate Name: NAPROXEN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 230.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]\nPITAVASTATIN SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]\nPITAVASTATIN SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\n[82Rb+].[Cl-]\nName: RUBIDIUM CHLORIDE RB 82\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 117.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\n[82Rb+].[Cl-]\nName: RUBIDIUM CHLORIDE RB 82", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 117.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCCCCC/C=C\\CCCCCCCC(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 282.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.11 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCCCCC/C=C\\CCCCCCCC(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 282.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.11 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2.O=C(O)/C=C\\C(=O)O\nName: INDACATEROL MALEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 508.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2.O=C(O)/C=C\\C(=O)O\nName: INDACATEROL MALEATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 508.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cc2c(cc1CC1=NCCN1)C1CCC2CC1\nName: METRAFAZOLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cc2c(cc1CC1=NCCN1)C1CCC2CC1\nName: METRAFAZOLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nOC[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCOCc1ccc(-c2ccccc2)c(F)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 433.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nOC[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCOCc1ccc(-c2ccccc2)c(F)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 433.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOS(=O)(=O)c1cc(C(C)(C)C)cc2cc(C(C)(C)C)ccc12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 348.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOS(=O)(=O)c1cc(C(C)(C)C)cc2cc(C(C)(C)C)ccc12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 348.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(c1cc2ccccc2o1)N1CCN(Cc2ccccc2)CC1\nCandidate Name: BEFURALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 320.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(c1cc2ccccc2o1)N1CCN(Cc2ccccc2)CC1\nCandidate Name: BEFURALINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 320.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nC#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ERLOTINIB\n\n### Structure\n```\nC#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 393.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.41 | 0-5 | ‚úì |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 74.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.420\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nC#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1", "output": "## Molecular Property Analysis: ERLOTINIB\n\n### Structure\n```\nC#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 393.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.41 | 0-5 | ‚úì |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 74.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.420\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CCC(c1ccc(Br)cc1)c1ccccn1\nCandidate Name: BROMPHENIRAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 319.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CCC(c1ccc(Br)cc1)c1ccccn1\nCandidate Name: BROMPHENIRAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 319.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN/C(=N\\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1\nIBIPINABANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 487.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN/C(=N\\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1\nIBIPINABANT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 487.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCCCCCCC(=O)OC1CC(C)=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC2(C)C)C(C)(C)C1\nName: XANTOFYL PALMITATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1045.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCCCCCCC(=O)OC1CC(C)=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC2(C)C)C(C)(C)C1\nName: XANTOFYL PALMITATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1045.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)NC[C@H](O)c1ccc(O)c(O)c1\nDrug Name: LEVISOPRENALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)NC[C@H](O)c1ccc(O)c(O)c1\nDrug Name: LEVISOPRENALINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCNCC(N)=O\nDrug Name: MILACEMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 144.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCNCC(N)=O\nDrug Name: MILACEMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 144.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2.O=C(O)/C=C\\C(=O)O.O=C(O)/C=C\\C(=O)O\nName: THIETHYLPERAZINE MALEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2.O=C(O)/C=C\\C(=O)O.O=C(O)/C=C\\C(=O)O\nName: THIETHYLPERAZINE MALEATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 576.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 576.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.85 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C1c2ccccc2S(=O)(=O)N1CCCN1CCN(c2ncccn2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 387.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C1c2ccccc2S(=O)(=O)N1CCCN1CCN(c2ncccn2)CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 387.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C1c2ccccc2C(=O)C1c1ccc(F)cc1\nName: FLUINDIONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C1c2ccccc2C(=O)C1c1ccc(F)cc1\nName: FLUINDIONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CEFTIZOXIME\n\n### Structure\n```\nCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 383.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.56 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 9.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 147.2 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.350\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1", "output": "## Molecular Property Analysis: CEFTIZOXIME\n\n### Structure\n```\nCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 383.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.56 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 9.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 147.2 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.350\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1nc2c(N3CCNCC3)cccc2n1S(=O)(=O)c1ccccc1\nPF-05212377\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1nc2c(N3CCNCC3)cccc2n1S(=O)(=O)c1ccccc1\nPF-05212377", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCOCCOC(=O)c1cccnc1\nCandidate Name: NICOBOXIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 223.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCOCCOC(=O)c1cccnc1\nCandidate Name: NICOBOXIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 223.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Cn1cnnn1)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nncs3)CS[C@H]12\nDrug Name: CEFTEZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 440.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 156.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Cn1cnnn1)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nncs3)CS[C@H]12\nDrug Name: CEFTEZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 440.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 156.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)N(C)c1c(I)c(C(=O)O)c(I)c(N(CC(O)COCCCCOCC(O)CN(C(C)=O)c2c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c2I)C(C)=O)c1I\nIOZOMIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1458.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)N(C)c1c(I)c(C(=O)O)c(I)c(N(CC(O)COCCCCOCC(O)CN(C(C)=O)c2c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c2I)C(C)=O)c1I\nIOZOMIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1458.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 365.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 365.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)NC(Cc1ccc(C)cc1)c1ccccc1\nDrug Name: MOCTAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 473.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 9.21 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)NC(Cc1ccc(C)cc1)c1ccccc1\nDrug Name: MOCTAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 473.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 9.21 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3\nCandidate Name: SAMIDORPHAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3\nCandidate Name: SAMIDORPHAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O.Cc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O.O.O=S(=O)(O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1144.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O.Cc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O.O.O=S(=O)(O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1144.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCCCCCCOc1nsnc1C1=CCCN(C)C1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: XANOMELINE\n\n### Structure\n```\nCCCCCCOc1nsnc1C1=CCCN(C)C1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 281.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.22 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 38.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.720\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCCCCCCOc1nsnc1C1=CCCN(C)C1", "output": "## Molecular Property Analysis: XANOMELINE\n\n### Structure\n```\nCCCCCCOc1nsnc1C1=CCCN(C)C1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 281.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.22 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 38.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.720\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1\nFOSNETUPITANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1\nFOSNETUPITANT", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCC(=O)C(c1ccccc1)(c1ccccc1)C(C)CN(C)C\nISOMETHADONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCC(=O)C(c1ccccc1)(c1ccccc1)C(C)CN(C)C\nISOMETHADONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nC[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: METHYLDOPA\n\n### Structure\n```\nC[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 211.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.44 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 103.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nC[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O", "output": "## Molecular Property Analysis: METHYLDOPA\n\n### Structure\n```\nC[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 211.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.44 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 103.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COCC[n+]1c2c(n(Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O\nDrug Name: SEPANTRONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 363.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COCC[n+]1c2c(n(Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O\nDrug Name: SEPANTRONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 363.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ETORICOXIB\n\n### Structure\n```\nCc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 358.9 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.18 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 59.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.700\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1", "output": "## Molecular Property Analysis: ETORICOXIB\n\n### Structure\n```\nCc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 358.9 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.18 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 59.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.700\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNC(=O)C1CN(CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)CCN1CC(=O)Nc1c(Cl)cc(N)cc1Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 604.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.27 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNC(=O)C1CN(CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)CCN1CC(=O)Nc1c(Cl)cc(N)cc1Cl", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 604.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.27 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCc1ncc([N+](=O)[O-])n1CCO\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: METRONIDAZOLE\n\n### Structure\n```\nCc1ncc([N+](=O)[O-])n1CCO\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 171.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.09 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 81.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.520\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCc1ncc([N+](=O)[O-])n1CCO", "output": "## Molecular Property Analysis: METRONIDAZOLE\n\n### Structure\n```\nCc1ncc([N+](=O)[O-])n1CCO\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 171.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.09 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 81.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.520\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@]12CC[C@H]([N+]3(C)CCCC3)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CCC[N+]2(C)C\nName: CANDOCURONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 386.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.39 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@]12CC[C@H]([N+]3(C)CCCC3)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CCC[N+]2(C)C\nName: CANDOCURONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 386.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.39 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl\nName: AZOSEMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 126.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl\nName: AZOSEMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 370.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 126.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN1CCC(N(Cc2ccccc2)c2ccccc2)CC1\nName: BAMIPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 280.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN1CCC(N(Cc2ccccc2)c2ccccc2)CC1\nName: BAMIPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 280.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1\nDrug Name: EBASTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 469.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.22 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1\nDrug Name: EBASTINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 469.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.22 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1\nName: PROBENECID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1\nName: PROBENECID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1\nDrug Name: DEMBREXINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 379.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1\nDrug Name: DEMBREXINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 379.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ncc(CO)c(C=O)c1O\nDrug Name: PYRIDOXAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 167.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ncc(CO)c(C=O)c1O\nDrug Name: PYRIDOXAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 167.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\n[K]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 39.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\n[K]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 39.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCN[C@H](C)Cc1cccc(C(F)(F)F)c1\nDrug Name: LEVOFENFLURAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 231.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCN[C@H](C)Cc1cccc(C(F)(F)F)c1\nDrug Name: LEVOFENFLURAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 231.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C\nName: RIFAMPIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 823.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 220.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C\nName: RIFAMPIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 823.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 220.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC[N+](CC)(CC)CC\nCandidate Name: TETRYLAMMONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 130.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC[N+](CC)(CC)CC\nCandidate Name: TETRYLAMMONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 130.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1\nELAFIBRANOR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1\nELAFIBRANOR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 546.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 142.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 546.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 142.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1\nName: TOCOTRIENOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.68 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1\nName: TOCOTRIENOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.68 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC#C[C@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C\nName: DIMETHISTERONE ANHYDROUS\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 340.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC#C[C@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C\nName: DIMETHISTERONE ANHYDROUS", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 340.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1\nName: PIRPROFEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 251.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1\nName: PIRPROFEN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 251.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O\nDrug Name: SAGOPILONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 543.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.46 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O\nDrug Name: SAGOPILONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 543.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.46 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1\nCandidate Name: ALDOXORUBICIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 750.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 267.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1\nCandidate Name: ALDOXORUBICIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 750.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 267.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCNC(C)C(O)c1ccc(O)c(O)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DIOXIFEDRINE\n\n### Structure\n```\nCNC(C)C(O)c1ccc(O)c(O)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 197.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.74 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCNC(C)C(O)c1ccc(O)c(O)c1", "output": "## Molecular Property Analysis: DIOXIFEDRINE\n\n### Structure\n```\nCNC(C)C(O)c1ccc(O)c(O)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 197.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.74 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: N#CC(c1ccc(Cl)cc1)c1ccc(-n2ncc(=O)[nH]c2=O)cc1Cl\nDrug Name: CLAZURIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: N#CC(c1ccc(Cl)cc1)c1ccc(-n2ncc(=O)[nH]c2=O)cc1Cl\nDrug Name: CLAZURIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c([O-])c(=O)n2C)o1.[K+]\nDrug Name: RALTEGRAVIR POTASSIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 152.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c([O-])c(=O)n2C)o1.[K+]\nDrug Name: RALTEGRAVIR POTASSIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 152.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO\nIOTHALAMATE MEGLUMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 809.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO\nIOTHALAMATE MEGLUMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 809.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C1c2c(O)cccc2Cc2cccc(O)c21\nANTHRALIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 226.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C1c2c(O)cccc2Cc2cccc(O)c21\nANTHRALIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 226.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CCCSc1c2ccccc2nn1Cc1ccccc1\nDAZIDAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CCCSc1c2ccccc2nn1Cc1ccccc1\nDAZIDAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)Nc1cc([As](=O)(O)O)ccc1O\nACETARSONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 275.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)Nc1cc([As](=O)(O)O)ccc1O\nACETARSONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 275.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12\nOSI-930\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.06 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12\nOSI-930", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.06 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O\nCandidate Name: POLMACOXIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O\nCandidate Name: POLMACOXIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCO[P@](=O)(c1cc(C)cc(/C=C/C#N)c1)c1c(C(N)=O)[nH]c2ccc(Cl)cc12\nName: FOSDEVIRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 413.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCO[P@](=O)(c1cc(C)cc(/C=C/C#N)c1)c1c(C(N)=O)[nH]c2ccc(Cl)cc12\nName: FOSDEVIRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 413.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ROSARAMICIN\n\n### Structure\n```\nCC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 581.8 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 2.67 | 0-5 | ‚úì |\n| H-Bond Acceptors | 10.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 135.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.270\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C", "output": "## Molecular Property Analysis: ROSARAMICIN\n\n### Structure\n```\nCC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 581.8 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 2.67 | 0-5 | ‚úì |\n| H-Bond Acceptors | 10.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 135.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.270\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C\nCandidate Name: FINASTERIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C\nCandidate Name: FINASTERIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCCN1CCC(C(=O)c2ccc(F)cc2)CC1)c1ccc(F)cc1\nDrug Name: LENPERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCCN1CCC(C(=O)c2ccc(F)cc2)CC1)c1ccc(F)cc1\nDrug Name: LENPERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[N+](C)(C)CCO.C[N+](C)(C)CCO.O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.O=S(=O)([O-])[O-].[Mg+2]\nDrug Name: SALCOLEX\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 602.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[N+](C)(C)CCO.C[N+](C)(C)CCO.O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.O=S(=O)([O-])[O-].[Mg+2]\nDrug Name: SALCOLEX", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 602.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCCNC1(c2ccccc2)CCCCC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ETICYCLIDINE\n\n### Structure\n```\nCCNC1(c2ccccc2)CCCCC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 203.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.46 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 12.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.790\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCCNC1(c2ccccc2)CCCCC1", "output": "## Molecular Property Analysis: ETICYCLIDINE\n\n### Structure\n```\nCCNC1(c2ccccc2)CCCCC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 203.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.46 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 12.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.790\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCOc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DICLOFENSINE\n\n### Structure\n```\nCOc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 322.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.58 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 12.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCOc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1", "output": "## Molecular Property Analysis: DICLOFENSINE\n\n### Structure\n```\nCOc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 322.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.58 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 12.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCc1nc2c(C)cc(-c3cn4c(n3)CCCC4)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1\nName: POMISARTAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 490.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCc1nc2c(C)cc(-c3cn4c(n3)CCCC4)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1\nName: POMISARTAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 490.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21.[Br-].[Br-]\nHEXAFLUORENIUM BROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 662.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.24 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21.[Br-].[Br-]\nHEXAFLUORENIUM BROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 662.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.24 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: c1ccc2ccccc2c1\nCandidate Name: NAPHTHALENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 128.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: c1ccc2ccccc2c1\nCandidate Name: NAPHTHALENE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 128.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCC1(CCOC(N)=O)C(=O)NC(=O)NC1=O\nCandidate Name: CARBUBARB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 127.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCC1(CCOC(N)=O)C(=O)NC(=O)NC1=O\nCandidate Name: CARBUBARB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 127.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O\nDrug Name: LEVOGLUCOSE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O\nDrug Name: LEVOGLUCOSE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nOC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: COFORMYCIN\n\n### Structure\n```\nOC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 284.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -2.21 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 9.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 5.0 | ‚â§5 | ‚úì |\n| PSA | 132.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.420\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nOC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O", "output": "## Molecular Property Analysis: COFORMYCIN\n\n### Structure\n```\nOC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 284.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -2.21 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 9.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 5.0 | ‚â§5 | ‚úì |\n| PSA | 132.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.420\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)OCc2ccccc2-n2cccc21\nName: ZALDARIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 428.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)OCc2ccccc2-n2cccc21\nName: ZALDARIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 428.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)c1cc(C(C)C)c(-c2csc(N(CCN(C)C)Cc3cccnc3)n2)c(C(C)C)c1\nName: FOROPAFANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 464.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.14 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)c1cc(C(C)C)c(-c2csc(N(CCN(C)C)Cc3cccnc3)n2)c(C(C)C)c1\nName: FOROPAFANT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 464.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.14 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCN(c1ccncc1)n1ccc2ccccc21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 251.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCN(c1ccncc1)n1ccc2ccccc21", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 251.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)OCC)C[C@@H]2CCCC[C@@H]21)C(=O)O\nORBUTOPRIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)OCC)C[C@@H]2CCCC[C@@H]21)C(=O)O\nORBUTOPRIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
